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1 INTRODUCTION 
1.1 General Introduction 
A drug profile is continuously refined and qualified with progressive understanding of its 
pharmacokinetics (PK) and pharmacodynamics (PD). Traditionally, understanding of PK [PD] 
behaviour has been based on fitting a mathematical model to data obtained from highly 
selected individuals. The obtained model should then give the opportunity to predict the 
extent and time course of the exposure [related to a pharmacological effect and adverse 
events] and to optimise therapeutic outcomes (Rowland and Tozer 1989; Derendorf et al. 
2000; Gieschke and Steimer 2000). In fact, PK and PD are complex processes in nature with a 
high degree of variability due to the impact of a myriad of interactions that arise from 
differences in the pathophysiologic, demographic and/or genotypic characteristics between 
individuals, or over time within a given individual (Rowland and Tozer 1989). Unfortunately, 
such variability can potentially affect all PK and PD parameters estimates. The precise 
assessment of such variability is hampered by estimates of uncertainty (Bois 2001), which 
are basically due to a lack of knowledge on the variability stemming from various sources, 
including model simplifications or misspecifications (Nestorov 2001; Gueorguieva et al. 
2005). 
Pharmacokinetic and pharmacokinetic evaluations can be performed by modelling data 
either from each subject (“individual approach”) or from a group of individuals together 
(“population approach”). The individual approach requires intensive individual sampling to 
draw reliable conclusions; however, in many cases (and for ethical and/or clinical reasons), 
only limited samples are possible. For instance, the frequent withdrawal of blood samples 
may  not be a feasible basis for PK/ PD investigations in the case of HIV-infected (Roos et al. 
2008), anaemic (Vincent et al. 2006) or paediatric (Cole et al. 2006) populations. 
Furthermore, individual subjects provide insufficient information due to the fact that not all 
aspects are exhibited by all subjects or that the model specifications are simply not 
appropriate. For instance, it is common in pharmacokinetics that a one-compartment model 
can frequently fit plasma concentration data of a particular drug from some individuals, but 
a two-compartment model is needed to fit data from other individuals in the same study 
(Schoemaker and Cohen 1996; Bonate 2006). Considerable interindividual variability in 
plasma concentration levels (and consequently the therapeutic outcome) of many drugs like 
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antidepressants and anticoagulants has been recently explained by genetic and demographic 
factors (Lessard et al. 1999; Ma et al. 2004; Stehle et al. 2008). These examples show that 
the individual approach can mask an important PK characteristic that may have serious 
outcomes, especially if these drugs are of narrow therapeutic index or potentially interact 
with other drugs (Lessard et al. 1999; Hughes et al. 2004; Hung et al. 2005). 
 
It has been recognized that the most effective tool to deal with these problems is the 
application of the population approach. The data provided by different subjects can be 
integrated (Schoemaker and Cohen 1996) and the subjects’ characteristics can be co-
analyzed to obtain adequate parameter estimates. Because of its ability to partly disentangle 
the uncertainty from the variability, the population approach can produce a general model 
of sensible parameter estimates, which differ randomly between individuals (Bois 2001). The 
obtained model should then enable description of the data for each and all individuals 
adequately (Sheiner and Ludden 1992; Ette et al. 2004). Extensive contextualization of the 
methodology and the applications of this approach in drug development are available 
(Gieschke and Steimer 2000; Ette, E.I. and Williams, P.J. 2007; Grasela et al. 2007). 
 
For the current study, I shall provide a relevant framework of this approach and potential 
examples of its applications before embarking on modelling the drug probes of interest; 
fluorescein, clarithromycin, dextromethorphan and phenprocoumon. Although the context 
presented here will be illustrated with pharmacokinetics in most cases, the general 
principles are applicable to pharmacodynamics as well, unless stated otherwise. 
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1.2 Aim of the Thesis 
The overall aim of the thesis was to quantify selected pharmacokinetic and/or 
pharmacodynamic characteristics of specific probe drugs utilizing the advantages of the 
population analysis approach. By accounting for the between-subject variability in the 
population approach, the final developed model is expected to carry great advantages 
compared to standard non-compartmental analysis. Simulation of final models outcomes in 
addition to prior information about respective drugs pharmacology were used to build a 
confidence about the utility of the presented models.  
 
The specific aims are to: 
- Compare the ocular pharmacokinetics of a lyophilisate formulation in relation to eye 
drops and to develop an empiric ocular population pharmacokinetic model describing 
concentrations in the cornea and anterior chamber adequately. Fluorescein sodium 
was selected as a probe drug because it is safe and extensively used as a diagnostic 
substance in ophthalmology and because local concentrations can be determined 
non-invasively by flurophotometry. 
- Quantitatively describe the nonlinearity in the pharmacokinetics of clarithromycin in 
the presence of its active metabolite, 14(R)-hydroxy-clarithromycin and to better 
understand the time course of inhibition via population pharmacokinetic modelling. 
These data are important for a better understanding of the underlying processes and 
for the assessment of dose adjustments of clarithromycin and co-administered 
CYP3A4 substrates. 
- Assess the activity of individual CYP2D6 alleles with regard to the clearance of 
dextromethorphan to dextrorphan. These data are needed for a better prediction of 
CYP2D6 activity from genotypes for respective dose adjustments of CYP2D6 
substrates. 
- Develop a general population PK/PD model for phenprocoumon that combines 
demographic and genetic covariates to explain the variability of the entire dose-
exposure-response relationship. This information is a prerequisite for prediction of 
the individual optimal phenprocoumon dosing based on mechanistic rather than 
empirical considerations.  
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1.3 Overview of Population Approaches 
 
1.3.1 Definitions 
According to the definition of the US Food and Drug Administration (FDA), Population 
pharmacokinetics (PopPK) is “the study of the sources and correlates of variability in drug 
concentrations among individuals who are the target patient population receiving clinically 
relevant doses of a drug of interest”. Certain patient demographical, pathophysiological, and 
therapeutic features, such as body weight, age, excretory and metabolic functions, and the 
presence of other therapies, can regularly alter dose–concentration relationships (FDA 
1999). However, there is currently no definition for population pharmacodynamics (PopPD) 
provided by the FDA. PopPD aims to interpret and describe the sources and correlates of 
variability in therapeutic outcome, in a quantitative fashion and in a target population 
receiving clinically relevant doses (Ette, E.I.  and Williams, P.J. 2007). The Population Model 
is an elaborate statistical model which deals with identifying and quantifying the types, 
degrees and causes of differences within and between individuals, often depending on 
sparse pharmacokinetic/pharmacodynamic data (Williams and Ette 2007). The 
comprehensive field of drug evaluations that involves the development or estimation of 
pharmacokinetics, pharmacodynamics, linking pharmacodynamic–outcomes and disease 
progression models, is called pharmacometrics (Ette, E.I. and Williams, P.J. 2007). 
In the arena of pharmacometrics, simulation is defined as the generation of data using 
certain types of mathematical and probabilistic models describing the behaviour of the 
system under study. It provides convincing objective evidence of the merits of a proposed 
study design and analysis (FDA 1999). 
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1.3.2 Theory of Population Approach   
 
Within the framework of population nonlinear mixed effects models, and if the data come 
from j=1, …, N individuals, then the observed response of interest, e.g., plasma 
concentration, in an individual can be described as 
                                                                  Yij= f(j, x) + εij 
 
where the dependent variable Yij for i = 1, . . . , nj is the response of interest (e.g. drug 
concentrations) of the jth subject. The symbol f stands for a function that predicts the 
response in the jth subject (e.g., one or several exponentials), which is a function of known 
quantities, x (time of observation, drug dose) and parameters,  (drug clearance, volume of 
distribution, rate constant). The quantities in x are known, because they are either measured 
or controlled, and therefore, are called “fixed effects”. The parameters in the i vector are 
called “fixed effect parameters” because they quantify the influence of the fixed effects on 
the dependent variable. The individual j is assumed to arise from some multivariate 
probability. The last part of the previous equation, εij is the residual error of the model, i.e., 
the ith measurement of the difference between the observed and the predicted response in 
the jth subject. It is assumed to come from probability distributions with a mean of zero and 
the same (usually unknown) variance. If the distribution of εij is assumed to be normal, with 
zero mean and uniform variance, then the maximum likelihood estimation reduces to 
ordinary least squares estimation. Although the function j will differ between individuals, it 
is realistic to assume that the set of model structural parameters is qualitatively the same for 
all individuals and that the parameters vary quantitatively among individuals. 
Mathematically this can be written as 
                                                               j =g (θ, zj) + ηj 
 
where g is a known function that describes the expected value of j as a function of 
individual specific covariates zj, such as weight, age etc., and the vector of population 
parameters θ. The symbol ηj represents the random variation of the individual parameter 
vectors around the population prediction. The ηj is usually assumed to be independent 
across individuals (i.e., ηj, ηl are independent for j ≠ l) and follow a lognormal distribution 
with a median of 1 and a constant coefficient of variation. It does not follow that each θ 
must have a corresponding η. Because this model describes the influence of both fixed and 
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random effects, it is called a “mixed effect model” (Sheiner and Beal 1980; Ette and Williams 
2004; Bonate 2006). 
 
1.3.3 Software 
Many software programs have been widely used in PopPK and PopPD such as NONMEM 
(Beal and Sheiner 1980), ADAPT (D’Argenio and Schumitzky 2008), and MONOLIX (Lavielle 
and Mentre 2007). These programs differ in the number of assumptions made regarding the 
statistical distribution of the estimated parameters (Aarons 1999; Bauer et al. 2007). They 
take either a parametric approach with strong assumptions (typically of a Gaussian 
distribution (Beal and Sheiner 1980; Lindstrom and Bates 1990) or Bayesian approach (Lunn 
et al. 2002)), a semiparametric view with relaxed assumption (Verotta et al. 1989; Wang, Y et 
al. 2008) or a nonparametric (no assumption) approach (Mallet et al. 1988; Jelliffe et al. 
2000). During modelling, the program uses a minimization routine to fine-tune an initial set 
of model parameter estimates specified by the user. This process repeats through several 
iterations until the model has reached convergence. 
1.3.4 Types of Models 
Population models are commonly classified into descriptive and predictive models according 
to their functions or to mechanistic and empirical models according to their principle. 
Unlike predictive models, descriptive models are derived from certain data and cannot be 
extrapolated. For instance, the linear concentration-effect relationship may not be 
extrapolated beyond the range of observed concentrations but the Emax-type models can be 
used. The danger of extrapolating the descriptive model in this case could be a high 
incidence of side effects due to greater exposure of the drug (Gobburu 2004; Bonate 2006). 
Likewise, mechanistic models allow direct and/or indirect linkage to physiological processes, 
whereas empiric models do not allow such relation. Mechanistic models, such as 
physiological-based pharmacokinetic models are based on physical and physiological 
principles and should have as many features of the system incorporated into the model as 
the data allow (Thakur 1991; Bonate 2006).  
Actually, most known population models are said to be hybrid models, i.e., mechanistic in 
areas where the physiology and pharmacology of the system are understood and empirical 
in places that are still black boxes. 
INTRODUCTION 
 
7 
 
1.3.5 Model Development and Evaluation Strategies 
The process of model development usually begins with appropriate identification of the 
model structure based on physiological and mathematical bases that serve its usefulness 
(Ette et al. 2003; Bonate 2006). To identify the model appropriately, prior information 
regarding the model parameters and the influencing covariates are very helpful to specify 
and optimize the model structure (Maitre et al. 1991). Data visualization usually guides and 
determines the model building strategy, and hence directly influences the efficacy with 
which the final model is derived. Other means that guide model development should include 
objective function minimization and inclusion of random parameters and covariates (Ette 
and Ludden 1995; Jonsson et al. 2007). 
Modelling both PK and PD data can be done either sequentially or simultaneously. In the 
sequential modelling, the PD is conditioned on the PK estimates. In the simultaneous model, 
the parameters are considered to be jointly distributed and the flow of information is 
bidirectional (Williams et al. 2001; Zhang et al. 2003a; Zhang et al. 2003b). Both approaches 
appear to provide similar results (Davidian and Giltinan 1993; Zhang et al. 2003a).  
In many cases, a link model between PK and PD data provides the essential integrated step 
to arrive at an enlightened understanding of the dose-exposure-response relationship. This 
link can be described directly or indirectly by many models, e.g., mechanistic or empirical 
models (Williams et al. 2001; Williams and Ette 2007). 
Once the model is developed, it should be evaluated for its reliability, potential 
misspecifications and for its stability (Ette et al. 2003; Bonate 2006). Reliability of a final 
model can be checked via the assessment of the uncertainty of the parameters and random 
effects (Ette et al. 1998; Williams et al. 2007). Mis-specifications and systematic error can be 
identified through goodness-of-fit plots, which include plots of predicted values, residuals 
and the possible impact of individuals’ covariates. These plots provide helpful information 
about whether the model addresses all relevant aspects of data or whether part(s) of the 
model need(s) further attention (Logan 2003; Williams et al. 2007). In addition, visual 
predictive check plots and simulated graphics are also helpful to ensure adequate model 
performance (Post et al. 2008). Indeed, simulation has recently gained recognition as a 
useful tool for providing more informed and scientifically sound decision-making regarding 
the developed model and its logical implications (FDA 1999; Holford 2006; Williams and Ette 
2007) and any future changes in the drug profile towards new dosing schedules (Hamberg et 
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al. 2007; Nomura et al. 2008). The final model stability can be assessed by its resistance to 
data change (Ette 1997; Williams et al. 2007) or by omitting a portion of the data and 
comparing the result of the reduced data set with those of the full data set (Zandvliet et al. 
2005). 
1.3.6 Properties of the Final Model 
The final model should at least be useful as “the true or right” model is unknown. For a 
population model to be useful, it should represent the interaction between the drug and the 
biological system. Since general effects in a clinical data set can be blurred by other sources 
of variation or by random effects, a useful model should provide a summary of the data in 
terms of the fixed effects and the nature and magnitude of the random effects. It should 
mimic the complexity of biological processes. A gross complex model is, in general, difficult 
to solve numerically, difficult to interpret and may falsely convey confidence in the study 
findings. On the other hand, a very simple model can lead to loss of information about the 
biological system. In these circumstances, balanced assumptions are needed for the model 
to be descriptive and the biological system or process to be predictive (Haefner 1996; Kimko 
and Duffull 2003; Bonate 2006). Thus, a useful model should also be simple, transparent, 
applicable, informative, descriptive, predictive, retrodictive and valid (Bonate 2006; Ette, E.I. 
and Williams, P.J. 2007).  
 
 
1.4 Potential Examples of Modelling Pharmacokinetic-
Pharmacodynamic Processes 
Serious clinical consequences can be caused by variability, which in most cases can lead to 
unexpected or unusual characteristics in drug profiles. These features cannot be quantified 
by simple tools of analysis and thus extensive work is required. To come up with a useful 
model based on plausible concepts, it is essential to describe this variability at the level of 
the underlying processes.  
1.4.1 Absorption 
Drug absorption after oral administration is a highly variable process and an extremely 
complex phenomenon that depends upon the interaction between three types of variables; 
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(i) drug-specific variables, such as the physicochemical properties of the drug and its dosage 
form, etc, (ii) patient-specific variables, such as the (patho)physiology of the gastrointestinal 
tract, first pass effect, genetics, diet and concomitant drugs etc and (iii) population variables, 
such as the distribution of (patho)physiological factors (Petricoulo et al. 2007). 
When efficacy and/or safety are related to maximum drug concentration, it may be 
important to describe the absorption phase accurately (Kleinbloesem et al. 1987; Bagli et al. 
1996; Bagli et al. 1999). The occurrence of cardiotoxicity of fluoroquinolones, for instance, 
was related to their maximum concentration in plasma (Rubinstein and Camm 2002). The 
difficulty in dose adjustment of ophthalmic preparations may lead to potential ocular 
damage or systemic toxicity (Noecker et al. 2004; Fraunfelder 2006).  
More often, drug plasma concentration profiles are irregular shortly after oral 
administration and cannot be interpreted easily with conventional models based on first- or 
zero-order absorption kinetics and lag time (Zhou 2003). In such cases, more complex 
models are needed, such as those based on Weibull function (Zhou 2003; Rousseau et al. 
2004), inverse Gaussian input (Csajka et al. 2005; Wang, J et al. 2008), saturable time-
constraint absorption model (Piotrovskij et al. 1994) or those based on the Erlang (Rousseau 
et al. 2004) or Gamma (Debord et al. 2001) distribution. Actually, absorption kinetics are 
best described by a physiologically-based modelling approach, which should take into 
account the fairly complex interaction between the drug and the (patho)physiological 
environment of the gastrointestinal tract (Agoram et al. 2001; Van de Waterbeemd et al. 
2004; Willmann et al. 2004). However, development of such a model necessitates a large 
amount of data (Cai et al. 2006), which is seldom available in humans.  
It is common in clinical studies that few samples are taken during the absorption phase 
making absorption kinetics difficult to be characterized with precision. In this case, the 
absorption rate constant is needed to be fixed to a value based upon prior knowledge from 
the literature (Bonate 2006) or a constant rate infusion is defined up to the first sample 
(Csajka et al. 2002). It should be noted that fixing absorption parameters could lead to 
biased estimates of disposition and elimination parameters (Booth and Gobburu 2003; 
Carlsson et al. 2005). Furthermore, inappropriate estimation of absorption parameter(s) may 
arise due to a high correlation or co-linearity with other model parameters (Suverkrup 1985; 
Wang and Reuning 1992; Wade et al. 1993). Other issues concerning absorption modelling 
are that both rate and extent of absorption can vary over the duration of a study (Csajka et 
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al. 2002; Higaki et al. 2008) and also absorption profiles in healthy subjects may be not 
appropriate for patient populations.  
 
1.4.2 Distribution 
In general, interindividual variability in volume of distribution is less than that in other 
pharmacokinetic parameters (Breimer 1983). Most of the observed interindividual variability 
in drug distribution stems from differences in body size and composition, genetics, and/or 
alteration in protein binding due to pathophysiological changes or comedication (Banh et al. 
2002; De Paepe et al. 2002; Sutherland 2005).  
Part of this variability can be explained by one or more of subjects’ covariates, such as body 
weight, age, gender, etc., (Holford, N H 2002; Conil et al. 2007). Actually, modelling 
variability in distribution may involve the application of physiological-based pharmacokinetic 
models, especially where tissue binding is the main issue to be addressed (as in the case for 
toxicokinetics (Bjorkman et al. 2001)). However, the application of these models remains 
limited, in part due to information deficit and uncertainty regarding model parameters 
(Fisher et al. 1998; Brightman et al. 2006; Levitt and Schoemaker 2006).  
 
1.4.3 Clearance 
The most clinically useful parameter in drug therapy is clearance, because it reflects all the 
mechanisms of elimination and it is the only parameter that directly relates dose to the 
systemic drug exposure (AUC). Drug clearance is highly variable between individuals, hence 
its characterization provides the opportunity to optimize therapeutic regimens and to 
suggest dosage adjustments in specific conditions. This involves the recognition of different 
routes of elimination and situations in which drug clearance is commonly altered, such as 
hepatic or renal dysfunction.  
1.4.3.1 Variability in renal clearance 
For renally excreted drugs, gross changes in glomerular filtration or urine flow and/or pH will 
have a substantial effect on total clearance (Chiou 1986; Bonnacker et al. 1989) and may 
lead to either toxic effects or ineffective treatment (Rougier et al. 2003). Unlike plasma, 
which has a narrow pH range of 7.3 to 7.5, urine pH ranges from 4.5 to 8.5 and can influence 
drug re-absorption (Florence, A.T. and Attwood, D. 2006). Indeed, urine pH has been shown 
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to be a major determinant for the excretion of basic drugs like memantine [pKa=10.27] 
(Freudenthaler et al. 1998), flecainide [pKa = 9.3] (Hertrampf et al. 1991) and 
methoxyphenamine [pKa = 10.45] (Roy et al. 1987).  
Recently, high inter-individual variability in renal clearance of ampicillin, famotidine, 
cephalexin, and metformin was partly explained by genetic variations in renal transporter 
expression (Yin et al. 2006; Wang, Z J et al. 2008). 
1.4.3.2 Variability in hepatic clearance 
Drug metabolism mainly takes place in the liver and to a lesser degree in other tissues such 
as the small intestine, kidneys and lungs (Krishna and Klotz 1994; Fisher et al. 2001; Ding and 
Kaminsky 2003). Metabolizing enzymes are expressed with identical function and structure, 
but their abundance and activity varies from site to site (Lin and Lu 2001). This is recognized 
as an important source of PK and PD variability (McGilveray 2005; Garrido et al. 2006; Lehr 
et al. 2008). For example, there is a 20-fold difference in the abundance and activity of CYP 
enzymes in the liver compared to the small intestine (Thummel et al. 1996; Paine et al. 
1997). Interindividual differences in protein levels within this group of oxidizing enzymes are 
approximately 5-fold for CYP2C and CYP3A4, 12-fold for CYP2E1, 20-fold for CYP1A2, and 
>50-fold for CYP2A6, CYP2B6, and CYP2D6 (Lin 2006).  
Although most metabolizing enzymes are polymorphic, the major polymorphisms that have 
clinical implications are those related to the oxidation of drugs by CYP2D6, CYP2C9 and 
CYP2C19 (Sachse et al. 1997; Kirchheiner et al. 2004c; Ufer et al. 2004a; Henningsson et al. 
2005; Sconce et al. 2005; Yukawa and Mamiya 2006; Gaedigk et al. 2008; Hirt et al. 2008), 
acetylation by N-acetyltransferase type 2 (Kinzig-Schippers et al. 2005; Luck et al. 2009), and 
S-methylation by thiopurine methyltransferase (Cuffari et al. 2004; Chrzanowska et al. 2006; 
Bosch 2008). Individuals who inherit an impaired ability to catalyze one or more of these 
enzymatic reactions may be at an increased risk of concentration-related adverse effects and 
toxicity upon administration of standard doses. The natural interpretation of this is that 
these subpopulations represent individuals who do or do not have particular signals for gene 
activity and so would be expected to exhibit differential drug disposition (Hamberg et al. 
2007; Kaila et al. 2007). 
Multiple distributions are required to describe such variability in order to account for each 
apparently distinct subpopulation (i.e., extensive or poor metabolizers). Based on such 
mixed distributions, this strategy will end up with a hierarchical or “mixture” model, with 
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highly accurate parameter estimates (Grasmader et al. 2004; Kaila et al. 2007). Mixture 
models assume that one or more subpopulations of individuals can exist rather than 
assuming that the entire population is best described by unimodal distributions for random 
effects (Frame et al. 2003; Kaila et al. 2007; Lemenuel-Diot et al. 2007). A complete and 
useful mixture population model should describe each of the sub-populations through sub-
models that can be entirely different or share some features, including parameter values 
(Frame et al. 2003; Hamberg et al. 2007; Kaila et al. 2007). Mathematically, a model could be 
difficult to solve if the distribution is blended from more than one sub-population 
(Lemenuel-Diot et al. 2007) and misclassification could appear here, which is related to the 
overlapping region between each two adjacent distributions (Kaila et al. 2007). 
 
1.4.4 Metabolites  
It is well demonstrated that modelling only the parent drug data may not reveal the 
metabolic pathway properly and in most cases leads to an inappropriate description of the 
metabolic pathway (Cosson et al. 2007; Lindauer et al. 2008). This is because of missing 
information in the metabolite data set, such as the rate and extent of metabolism or the 
impact of covariates on the overall metabolic clearance (Kerbusch et al. 2003; Hamberg et al. 
2007; Hirt et al. 2008). Modelling metabolites can also lead to refinement of the underlying 
mechanism of interactions (Hassan et al. 1999; Huitema et al. 2001; de Jonge et al. 2005; 
Quinney et al. 2008), improvement of the overall pharmacodynamic profile of the drug 
(Garrido et al. 2006; Herd et al. 2007) and increase applicability of the model (Cosson et al. 
2007; Lindauer et al. 2008).  
In reality, evaluating metabolite data is challenging, especially if the metabolite was not 
administered separately. This is because metabolite parameters depend heavily on parent 
data and many are unidentifiable. For example, if the volume of distribution of a metabolite 
is unknown a priori, then all the model parameters are globally unidentifiable and only the 
relative rate of systemic drug conversion to metabolite can be determined (Evans et al. 
2001; van der Marel et al. 2003). In this case, the model should be simplified and fixing 
parameters to prior knowledge is necessary (Black et al. 2003; Cosson et al. 2007; Levi et al. 
2007). If the link between the drug and its metabolite is not correctly specified, then the fit 
to the drug will suffer and the key correlations could be lost for the reasons mentioned 
above. If this is the case, then sequential fitting would seem a sensible alternative. Further 
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information about this linkage could also be obtained by deconvolution (Karol and Goodrich 
1988; Weiss 1998).  
Different models have been proposed to provide quantitative insight into factors 
determining the concentration-time curve of a metabolite following intravenous and/or oral 
administration of the precursor drug (Weiss 1988; Taft et al. 1997; Evans et al. 2001; 
Kerbusch et al. 2003). The number of metabolites for which parameters can be estimated is 
not limited (Evans et al. 2001; de Jonge et al. 2005). 
1.4.5 Modelling Drug Response 
Clinicians have long been aware that patients may require very different doses of a drug to 
produce the same clinical response (Irwin 1964; Marchant 1981; Bagli et al. 1999; 
Kirchheiner et al. 2005). However, only since the advent of molecular biology has the 
contribution of genetics to drug response variability come into focus and explained some of 
the reasons behind this variability (Tucker 2000; Stehle et al. 2008). It is well known that 
genetic polymorphisms can cause variability in drug response as a result of varied drug 
metabolism (Scordo and Spina 2002; Lee 2007; Mega et al. 2009) and transporter (Bosch 
2008; Choi and Song 2008; Pacanowski et al. 2008) and receptor activity (Muszkat 2007; 
Mahesh Kumar et al. 2008; Rosskopf and Michel 2008; Werner et al. 2008). These 
parameters can also be modulated by many other demographic, pathophysiologic, 
environmental and/or subjective factors (Furst 1988; Lu 1998; Tucker 2000; El Desoky et al. 
2006). The net worth of genetic knowledge increases significantly when it is integrated into 
PK and/or PD models. This has been proved to be one of the pivotal factors explaining large 
portion of interindividual variability (Schalekamp et al. 2007; Limdi et al. 2008; Stehle et al. 
2008).  
The clinical profiles of oral anticoagulants such as warfarin, acenocoumarol and 
phenprocoumon share the features of narrow therapeutic index and wide interindividual 
variability in exposure, which attenuate the dose-response relationship (Ansell 2003; Ufer 
2005a; D'Andrea et al. 2008; Stehle et al. 2008). Variability in the extent of anticoagulation 
depends on not only CYP2C9 polymorphisms but also on polymorphisms associated with the 
vitamin K epoxide-reductase-complex (VKORC1). This suggests that genetics-based dose 
individualization will meet the general objective of optimizing safety and efficacy (Limdi et al. 
2008; Qazim et al. 2008; Spreafico et al. 2008; Stehle et al. 2008). Taking the warfarin 
example, the development of a predictive dosage algorithm incorporating genetic factors 
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showed that 54% of the variance in warfarin dose could be explained by a combination of 
genetic (CYP2C9 and VKORC), clinical and demographic factors. Use of this algorithm 
resulted in more than a 50% decrease in the risk of adverse drug reactions (Hamberg et al. 
2007; Gage et al. 2008). Further refinement of this model could lead to effective 
improvement in the use of warfarin as additional CYP4F2 variants have been recently 
reported to impact upon warfarin dose (Caldwell et al. 2008). These examples show how 
genetics have shed light on interindividual variability in response to drugs. They also 
represent cases in which gene penetrance and frequency are relatively high. For these 
reasons, identification, evaluation and management of drug response variability is a 
therapeutic premise. Finally, biomarkers such as the prothrombin time or the international 
normalized ratio (INR), blood glucose and protein adducts are also of significant value when 
they are related to a clinical response(Danhof et al. 2005). 
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1.5 Characteristics of Probe Drugs 
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1.5.1 Chemical Structures 
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Figure 1: Chemical structures of probe drugs  
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1.5.2 Bioavailability of Fluorescein for Ocular Administration 
 
Fluorescein, usually as fluorescein sodium, is used extensively as a diagnostic tool in 
ophthalmology. For example, it is used to help diagnose corneal ulcers and infections, to 
examine the circulation through ocular tissues (Manivannan et al. 2005), to evaluate tear 
turnover (Mochizuki et al. 2009), and to measure the corneal permeability and transport of 
the blood-ocular barriers (Cunha-Vaz and Maurice 1967; Nelson 1995). 
When a drug solution is instilled onto the cornea, it subjects to three processes: (1) corneal 
absorption into the eye, systemic absorption via conjunctiva and sclera, and a large volume 
is cleared out of the eye with the tears, of which a part is lost and a part is absorbed 
systemically (Ahmed and Patton 1985; Mitra 2003; Lee et al. 2004; Urtti 2006). As a result, 
drug absorption after topical instillation of a drug into the eye is incomplete. Indeed, not 
more than 5% of a dose instilled by eye drops enters the eye via the cornea (Schoenwald 
1990; Chastain 2003). 
Normally, the conjunctival fornix contains about 7–9 μL of tears with a physiological tear 
flow of about 1 μL/min (Mishima et al. 1966). Conventional ophthalmic bottles dispense 
drops of about 30-50 μL (Davies 2000; Chastain 2003). The maximum volume that can be 
contained in the conjunctival fornix without overflow is about 30 μL (Mishima et al. 1966). 
However, only about 10–15 μL remains in the pre-corneal area, and the rest is spilled out 
immediately from the lids at the time of drug application (Mishima et al. 1966; Fraunfelder 
and Meyer 1987). Beyond the rapid loss of the additional volume, instillation of eye drops 
also stimulates lacrimation and increases the turnover rate by 25–30% (Macdonald and 
Maurice 1991). This reaction further decreases the contact time between the drug and the 
cornea. Finally, most eye-drop solutions contain preservatives that may cause local irritation 
or even toxic endothelial degeneration with long-term therapy (Noecker 2001; Pisella et al. 
2002; Jaenen et al. 2007). Irritation increases blinking, which eliminates about 2 μl per blink 
(of the physiological 7–9 μl) out through the puncta into the nasolacrimal duct (Maurice and 
Mishima 1984). For these reasons, 80% or more of the instilled drug is lost in the first 15–30 
s via conjunctiva and lacrimal drainage and does not enter the eye (Patton and Francoeur 
1978; Fraunfelder and Meyer 1987; Ahmed 2003; Chastain 2003). Generally, drainage limits 
the drug/pre-corneal contact time to about 5 min (Chastain 2003; Macha et al. 2003). This 
drainage mechanism causes the drug to be systemically absorbed by the nasal mucosa or by 
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the gastrointestinal tract (Lee and Robinson 1986; Chang and Lee 1987; Lang 1995). For 
instance, ocular bioavailability of timolol is about 11% (Urtti et al. 1990), while the rest is 
systemically absorbed, and a reduction of more than 60% of timolol systemic absorption was 
achieved after nasolacrimal occlusion in humans (Zimmerman et al. 1984). In rabbits, ocular 
versus systemic bioavailability was reported to be about 2.5 vs. 46% for levobunolol (Tang-
Liu et al. 1987) and 9 vs. 74% for flurbiprofen (Tang-Liu et al. 1984), which implies that most 
of the drug dose is unavailable for efficacy. Topical instillation of more drops does not 
significantly improve the ocular bioavailability (Chrai et al. 1974; Patton and Francoeur 1978) 
but may increase systemic side effects of the drug, even to critical levels for some drugs such 
as beta blockers (Diamond 1997; Taniguchi and Kitazawa 1997; Hayreh et al. 1999). 
To overcome eye-drop limitations, different drug delivery systems have been developed 
such as liposomes (Lee et al. 1985; Hathout et al. 2007), exoplants (Pontes de Carvalho et al. 
2006), collagen shields (Reidy et al. 1990; Taravella et al. 1999), ocular inserts (Hornof et al. 
2003), mucoadhesives (Davies et al. 1992) and lyophilisate (Diestelhorst et al. 1999; 
Suverkrup et al. 1999). These systems differ from each other in safety, possibility of dose 
adjustment and targeting, pre-corneal residence time, patient compliance, simplicity of use, 
and cost. Advantages and disadvantages of most delivery systems have been reported 
elsewhere (Mitra 2003). Lyophilisates (Figure 2) have recently been suggested to be a 
favorable formulation for delivering a drug into the eye (Diestelhorst et al. 1999; Dinslage et 
al. 2002; Lux et al. 2003; Steinfeld et al. 2004). 
 
 
Figure 2: Application of ophthalmic lyophilisate (Lux et al. 2003) 
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The ophthalmic lyophilisate carrier system (OLCS) is prepared from a drop of a hydrophilic 
polymer solution, in which a drug is dissolved or dispersed and freeze-dried on the tip of a 
soft hydrophobic carrier strip. The drug is administered to the conjunctival fornix by wiping 
the lyophilisate over the lower eyelid. Upon contact with tear film and/or conjunctiva, the 
lyophilisate rapidly rehydrates and dissolves to release the incorporated substance 
(Diestelhorst et al. 1999). It is not washed out by immediate copious tear secretion 
(Suverkrup et al. 2004). Since the corneal contact time is increased and pre-corneal losses 
are reduced (Lux et al. 2003), ocular bioavailability of the active ingredient should be 
enhanced. Lyophilisate water content is less than 5% and thus too low for microbial growth 
or hydrolytic degradation of constituents. Therefore, neither preservatives nor buffer salts 
are required to ensure stability (Suverkrup et al. 2004). Clinical data from ophthalmic 
applications of this dosage form with fluorescein (Dinslage et al. 2002; Lux et al. 2003; 
Steinfeld et al. 2004), mitomycin C (Schraermeyer et al. 1999), and pilocarpine (Suverkrup et 
al. 1999) indicated a reduction of topical and systemic side effects, less discomfort, and more 
pronounced therapeutic effects compared to eye drops. 
 
 
1.5.3 Clarithromycin and Autoinhibition of Metabolism 
 
Clarithromycin is a broad spectrum macrolide antibiotic and widely used for the treatment 
of upper and lower respiratory tract and other infections (Fernandes et al. 1986; Sturgill and 
Rapp 1992; Langtry and Brogden 1997). Clarithromycin interacts with many drugs on the 
level of intestinal and hepatic metabolizing enzymes CYP3A (Gorski et al. 1998; Rodvold 
1999). This may change efficacy and tolerability of other co-administered CYP3A substrates. 
Clarithromycin is rapidly and nearly completely absorbed from the gastrointestinal tract 
(Ishii et al. 1998). Due to notable first pass metabolism, approximately 50% to 55% of an oral 
dose is bioavailable as clarithromycin in the systemic circulation (Chu et al. 1992a; Fraschini 
et al. 1993; Gorski et al. 1998). The free fraction of clarithromycin in plasma is about 0.3 in 
healthy volunteers (Chu, S Y et al. 1993; Traunmuller et al. 2007). Clarithromycin is widely 
distributed throughout the body with an apparent volume of distribution range from 126 to 
306 litres (Chu, S et al. 1993; Rodvold 1999; Traunmuller et al. 2007). Approximately 22% of 
an oral dose is recovered as parent compound, 18% in the urine and 4% in the faeces (Davey 
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1991). The elimination half-life (t1/2) of clarithromycin is dose- and time-dependent, and 
ranges from 2.7 to 4.8 hours (Ferrero et al. 1990b; Chu et al. 1992b; Chu, S et al. 1993; 
Traunmuller et al. 2007). In healthy subjects, the average total body clearance ranges from 
29 to 58 L/h and renal clearance from 6.7 to 12.8 L/h, depending on the amount and number 
of doses administered (Chu, S et al. 1993; Rodvold 1999). After single and multiple (7 doses) 
administration of 500 mg clarithromycin tablets, the apparent total body clearance was 
reported to decrease from 42.1 to 18.7 L/h (Chu, S et al. 1993; Traunmuller et al. 2007). As 
renal clearance does not change under these conditions, the nonlinearity is attributed to 
non-renal elimination mediated by cytochrome P450 metabolism (Chu, S et al. 1993). 
Clarithromycin is extensively metabolized into at least eight metabolites via three metabolic 
pathways; i.e. hydroxylation at the 14-position, N-demethylation and hydrolysis of the 
cladinose sugar. Secondary biotransformation was also evident (Ferrero et al. 1990b; Davey 
1991; Yamamoto et al. 2004). Metabolic pathways of primary biotransformation are given 
below in Figure 3. 
Clarithromycin hydroxylation at position 14 is stereospecific yielding the 14-hydroxy-(R)-
epimer as the main metabolite, which accounts for 20% of the parent drug metabolism 
(Ferrero et al. 1990b; Davey 1991; Langtry and Brogden 1997). Indeed, this metabolite 
contributes significantly to the overall antimicrobial effect of clarithromycin (Martin et al. 
2001; Yamamoto et al. 2004). Formation of this  main metabolite, is predominantly 
mediated by CYP3A4 (Rodrigues et al. 1997; Bruce et al. 2001; Suzuki et al. 2003; Yamamoto 
et al. 2004) and was suggested to be capacity-limited, which may in part account for the 
nonlinearity observed in clarithromycin pharmacokinetics (Chu, S et al. 1993). 
Clarithromycin is also a potent inhibitor of intestinal and hepatic CYP3A4 activity (Gorski et 
al. 1998; Pinto et al. 2005b) in a dose-dependent manner (Ushiama et al. 2002). It has been 
classified as a mechanism-based inhibitor (Zhou et al. 2005). Based on in vitro models, 
clarithromycin was predicted to cause a reduction in the steady-state concentration of liver 
CYP3A4 to approximately 39% of initial level (Mayhew et al. 2000). The mechanism of this 
auto-inhibition was reported to be reversible (Hung et al. 2005; Pinto et al. 2005b), 
irreversible (Gorski et al. 1998; Bruce et al. 2001; Pinto et al. 2005a) and suicide inhibition 
mediated by formation of a metabolic intermediate complex (Mayhew et al. 2000).  
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Figure 3: Primary metabolic pathways of clarithromycin in man (Ferrero et al. 1990a) 
 
 
For clarithromycin the ratio of the area under free plasma concentration-time curve to the 
minimum inhibitory concentration (fAUC/MIC) is considered as the most predictive PK/PD 
index (Craig et al. 2002; Tessier et al. 2002) and used to link the pharmacokinetic parameters 
to the most important antimicrobial pharmacodynamic parameter, i.e. minimum inhibitory 
concentration (MIC). Based on animal infection models, a derived target value of fAUC0-24 
plasma /MIC was assumed to be 35 h for clarithromycin (Craig et al. 2002; Tessier et al. 2002). 
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Actually, the adult dosage regimen of clarithromycin 500mg twice daily achieves an average 
area under the concentration-time curve of free drug fAUC0-24 of about 5.85 ±1.79 
mg•h/litre in plasma (Traunmuller et al. 2007), which may provide sufficient efficacy as long 
as the MIC value does not exceed 0.25 to 1.0 µg/mL (Rodvold 1999). However, this dosing 
regimen may be ineffective in the treatment of infections caused by pathogens with a drug 
MIC higher than 1µg/mL in plasma, or higher than 0.125 µg/mL in tissues where fAUC is 
lower, suggesting the need of administration of a higher dose (Noreddin et al. 2002; 
Traunmuller et al. 2007). Because of the nonlinear kinetics, it is difficult to predict fAUC 
changes achieved by higher doses.  
 
 
 
 
 
1.5.4 The Use of Dextromethorphan as a CYP2D Phenotyping Drug 
 
Dextromethorphan is an antitussive drug which is widely used to relieve non-productive 
cough associated with acute upper respiratory tract infection (Parvez et al. 1996; Lee et al. 
2000). Its pharmacokinetics is characterised by a rapid absorption from the gastrointestinal 
tract (ka= 2.6 +/- 0.9 h
-1) after oral administration and a large volume of distribution ranging 
from 1220 to 16491 Litres (Kazis et al. 1996; Moghadamnia et al. 2003). The apparent total 
clearance of dextromethorphan ranges from 75 L/hr to 4167 L/h (Kazis et al. 1996; Borges et 
al. 2005). Dextromethorphan undergoes rapid and extensive first-pass metabolism. Primary 
metabolic steps include formation of dextrorphan mainly by CYP2D6 and of 3-
methoxymorphinan by CYP3A (Barnhart 1980; Jacqz-Aigrain et al. 1993; Moghadamnia et al. 
2003). Both dextrorphan and 3-methoxymorphinan are further metabolized to 3-
hydroxymorphinan by CYP3A4 and CYP2D6, respectively (Jacqz-Aigrain et al. 1993). A 
schematic description of dextromethorphan elimination pathways is given in Figure 4.  
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Figure 4: Elimination pathways of dextromethorphan (Yu, A and Haining, R L 2001)  
 
 
The dominating metabolic pathway in the majority of the population is the conversion of 
dextromethorphan to dextrorphan by CYP2D6 (Kupfer et al. 1984; Yeh et al. 2003; Pope et 
al. 2004), contributing to more than 80% to the formation of dextrorphan (Schmider et al. 
1997; Yu, A and Haining, R 2001; Moghadamnia et al. 2003). The selectivity of dextrorphan 
formation via CYP2D6, in addition to its favourable safety and availability, has made 
dextromethorphan a probe of choice for CYP2D6 phenotyping (Frank et al. 2007; Fuhr et al. 
2007).  
It is well known that CYP2D6 is a highly polymorphic enzyme. Today, more than 83 allelic 
variants have been described (Zhou et al. 2009). Because the overall disposition of 
dextromethorphan is highly dependent upon CYP2D6 activity (Nielsen et al. 1990; Zhang et 
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al. 1992; Sachse et al. 1997), these polymorphisms contribute to a wide interindividual 
variation in its plasma levels (Labbe et al. 2000; Pope et al. 2004) and response (Sachse et al. 
1997; Abdul Manap et al. 1999; Labbe et al. 2000; Tucker 2000; Moghadamnia et al. 2003). 
For other CYP2D6 substrates such as antidepressants and antipsychotic drugs such variability 
can lead to failure of treatment in carriers of haplotypes coding for a very high CYP2D6 
activity or may expose individuals with low activity haplotypes to a high risk of toxicity (poor 
metabolizers) (Seeringer and Kirchheiner 2008; Laika et al. 2009). For some opioids such as 
dihydrocodeine, codeine and tramadol, where the active metabolite is formed by CYP2D6, 
vice versa failure is associated with low activity and toxicity with high activity genotypes 
(Kirchheiner et al. 2007; Kirchheiner et al. 2008).  
Because it is important to identify individuals at risk for therapeutic failure or adverse effects 
caused by aberrant CYP2D6 activity, different proposals have been made to establish simple 
useful systems for the prediction of CYP2D6 phenotype as a prerequisite to personalize 
therapy with CYP2D6 substrates based on genotype information (Kirchheiner et al. 2001). 
These systems suffer from potential pitfalls depending on the correctness of underlying 
assumptions which may compromise prediction accuracy. The classical procedure divided 
populations, usually based on the urinary metabolic ratio of dextrorphan over 
dextromethorphan and an arbitrary “cut-off” value, into poor and extensive metabolizers 
(Mahgoub et al. 1977; Eichelbaum et al. 1979), with poor metabolizers representing 
individuals carrying two non-functional CYP2D6 alleles. However, it is difficult to predict 
phenotype correctly of individuals who are heterozygous for an active CYP2D6 allele, as 
these individuals are characterized by a large variability in CYP2D6 phenotype (Bock et al. 
1994). To account for heterozygosity and gene duplications, intermediate and ultra-rapid 
metabolizers subgroups have subsequently been introduced into the classification creating a 
polymodal distribution (Sachse et al. 1997; Kirchheiner et al. 2001; Heller et al. 2006; 
Rebsamen et al. 2008). Further refinement was required to account for decreased activity of 
the CYP2D6*10 allele frequently occurring in Asians (Yue et al. 1998; Mihara et al. 1999). In 
addition, a semi-quantitative scoring system defining categories for CYP2D6 alleles have 
been developed (Kirchheiner et al. 2004a; Steimer et al. 2004). This system defined a 
CYP2D6 genotype score as the sum of the gene dose for both alleles, with 1 for fully 
functional alleles, 0.5 for reduced activity functional alleles, and zero for non-functional 
alleles (Steimer et al. 2004). Although these classifications have improved phenotype 
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predictions (Sachse et al. 1997), considerable variability within heterozygous groups has still 
been reported (Raimundo et al. 2000; Kirchheiner et al. 2001) and substantial overlap 
between intermediate and extensive metabolizer distributions has been observed (Gaedigk 
et al. 2008). 
In the most recent scoring system, the so-called activity score system defined CYP2D6 
genotype as the sum of presumed values assigned to individual alleles (Gaedigk et al. 2008). 
The phenotype scores were derived from urinary ratios of dextromethorphan. It assigned a 
value of 1, 0.5, and 0 for fully functional, reduced, and non-functional alleles Table 1. 
 
    Table 1: The activity score model (Gaedigk et al. 2008) 
Value assigned to allele Observed CYP2D6 alleles 
0 *3, *4, *4xN, *5, *6, *7, *16, *36, *40, *42, *56B 
0.5 *9, *10, *17, *29, *41, *45, *46 
1 *1, *2, *35, *43, *45xN 
2 *1xN, *2xN, *35xN 
 
 
Obviously, the score activity system assumes identical metabolic activity for different alleles 
of in each group. This is, however, valid for defective CYP2D6 alleles such as *4 and *3, but 
the assumption for fully functional alleles, for example *1 and *2 alleles, to have identical 
activity is questionable. An in vitro study of rCYP2D6 enzyme supports this classification for 
some CYP2D6 probe drugs such as metoprolol and debrisoquine, but not for 
dextromethorphan, where the intrinsic clearance value of CYP2D6*2 was half that of 
CYP2D6*1 for dextromethorphan O-demethylation (Bapiro et al. 2002). These observations 
warrant further assessment of individual activity of each allele directly from plasma 
concentration time profile of CYP2D6 probes. 
 
1.5.5 Understanding Variability in Phenprocoumon Response 
 
Phenprocoumon is a coumarin derivative oral anticoagulant drug used for the prevention 
and treatment of arterial and venous thromboembolic disorders (Bourgain and Wright 
1955). The maintenance dose ranges from 0.75 to 9 mg per day (Trenk et al. 1987). 
Phenprocoumon exerts its effect by inhibition of vitamin K epoxide reductase (VKOR), which 
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converts vitamin K from non-reduced to reduced form, leading to a decrease in prothrombin 
level (Hirsh et al. 1998). Its large interindividual pharmacokinetic variability and narrow 
therapeutic index render a close monitoring necessary (Schalekamp et al. 2007; Stehle et al. 
2008). 
Phenprocoumon is rapidly absorbed from the gastrointestinal tract with an absorption rate 
constant of 2.5 h-1 (Haustein and Huller 1994) and nearly complete bioavailability (Alberio 
2003). It has a volume of distribution of 10 - 14.4 L (Haustein and Huller 1994; Masche et al. 
1999). More than 99% of the drug is bound to plasma proteins (>99%) (Trenk et al. 1987; de 
Vries and Volker 1990) with a serum free fraction of about 0.51 ± 0.20 % (Russmann et al. 
2001). A long elimination half-life of about 5 days has been reported for phenprocoumon 
with a mean total apparent clearance of about 0.040-0.063 L/h (Kitteringham et al. 1984; 
Russmann et al. 2001; Kirchheiner et al. 2004c). About 40 % of the administered dose is 
excreted unchanged (Toon et al. 1985) and may be eliminated with the faeces (de Vries et al. 
1988). The remainder of 60 % undergoes hepatic hydroxylation and conjugation (Toon et al. 
1985). A schematic representation of phenprocoumon metabolicimination pathways is given 
below in Figure 5.   
The 4'-, 6-, 7-, and 8-hydroxy metabolites are the major metabolites formed mainly by 
CYP2C9 (He et al. 1999; Ufer et al. 2004c; Kammerer et al. 2005), however CYP3A4 and 
CYP2C8 may be involved to a less degree (Ufer 2005a). In comparison with other structurally 
and pharmacologically related drugs, warfarin or acenocoumarol, phenprocoumon 
metabolism is substantially less dependent on CYP2C9 activity (Kammerer et al. 2005; Ufer 
2005a), most probably due to higher contribution of other CYP enzymes (Freedman and 
Olatidoye 1994; Ufer et al. 2004c) and the involvement of bile and urine excretion pathways 
(de Vries et al. 1988; Edelbroek et al. 1990). 
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Figure 5: Metabolic  clearance pathways of phenprocoumon (Stehle et al. 2008) 
 
Previous studies have attributed a major part of interindividual differences in the 
pharmacokinetics of phenprocoumon to the genetic polymorphism of CYP2C9. A higher 
metabolic capacity was obtained for homozygous carriers of CYP2C9*1/*1 than CYP2C9 
*2/*3 or CYP2C9 *3/*3 genotype (Kirchheiner et al. 2004c; Schalekamp et al. 2004; Ufer 
2005b). In a study of 284 patients during a follow-up period of 6 months, carriers of CYP2C9 
*2 or *3 genotypes had an increased risk of phenprocoumon overanticoagulation compared 
with homozygous CYP2C9*1/*1 subjects (Schalekamp et al. 2004). Compared with 
homozygous carriers of CYP2C9*1, patients homozygous for CYP2C9*3 were estimated to 
need a 1.5-fold reduction in the mean dose phenprocoumon to achieve the same INR (Stehle 
et al. 2008). 
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On the other hand, polymorphism of the vitamin K epoxide reductase complex (VKORC1) 
was identified as an important factor to explain a major fraction in the variability between 
individuals in their response to warfarin (Wadelius et al. 2009), acenocoumarol (Schalekamp 
et al. 2006; Teichert et al. 2009), and phenprocoumon (Schalekamp et al. 2007; Werner et al. 
2009). The increased risk of bleeding called for dose reduction in carriers of at least one T 
allele compared to those carrying CC homozygous (Reitsma et al. 2005; Schalekamp et al. 
2007). Homozygous presence of the VKORC1 variant C1173T (*2) allele was related to 1.9-
fold lower empirical doses compared with the wild-type for phenprocoumon (Stehle et al. 
2008). Furthermore, the differences in phenprocoumon dose requirements between 
patients with different CYP2C9 genotypes are modified by the VKORC1 genotype 
(Schalekamp et al. 2007), and being a carrier of a combination of CYP2C9*3/*3 and VKORC1 
TT variants is associated with over-anticoagulation status. About 7.2% of the variability in 
phenprocoumon dose requirement was reported to be explained by the CYP2C9 genotype, 
while up to 28.7% of the variability was explained by the VKORC1 genotype. A combination 
of both genes in interaction with patient’s age and sex explained up to 54.7% of variability in 
the mean dose requirement of phenprocoumon (Schalekamp et al. 2007).  
Published studies drew their conclusions from pharmacokinetic studies in healthy 
populations or from direct determination of the effect of genetic variants on 
phenprocoumon dose requirements. Concentrations of phenprocoumon and its metabolites 
have not yet been measured for a better understanding of the genetic impact on dose-
response relationships in patients. Indeed, this information is a prerequisite for prediction of 
the individual optimal phenprocoumon dose based on mechanistic rather than empirical 
considerations. While this has already been implemented for warfarin (Klein et al. 2009), a 
similar approach may be helpful also for phenprocoumon despite its lower dependence on 
CYP2C9 because its long elimination half-live of 106 - 150 hours (Kitteringham et al. 1984; 
Russmann et al. 2001) delays the effect of any dose adjustments. 
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2.1 Fluorescein Data 
2.1.1 Clinical Studies and Ethical Conduct 
 
Forty-four healthy volunteers were enrolled in three open-label, randomized, clinical studies 
that had been approved by the Ethics Committee of the University of Cologne. All 
participants gave their written informed consent. In studies 1, 2, and 3, sodium fluorescein 
0.17% was applied to 10 (age range: 24–27 years), 22 (age range: 22–45 years), and 12 (age 
range: 23–33 years) subjects at the same doses as conventional, preservative-free 40-μL eye 
drops (Fluoreszein 0.17% SE Thilo, Alcon, Germany) to one eye and as a fluorescein-
containing lyophilisate to the fellow eye. 
To prepare the lyophilisate, 170 mg sodium fluorescein was dissolved in 10 mL of a 1% 
hypromellose solution, filtered through a 0.22-μm cellulose ester membrane and deposited 
in aliquots of 40 μl on sterilized poly(tetrafluoroethylene) carrier strips by pipetting. The 
strips were frozen and lyophilized under aseptic conditions either in a water vapor 
permeable container in a conventional laboratory freeze-dryer (Christ alpha 2–4, Osterode, 
Germany) or they were snap-frozen by evacuation and freeze-dried directly in a small glass 
chamber; thereafter, they were packed aseptically in sterilized test tubes. The resulting 
lyophilisate was hemispherical in shape with a radius of approximately 2.3 mm. The method 
has been described in detail (Dinslage et al. 2002; Lux et al. 2003; Steinfeld et al. 2004; 
Suverkrup et al. 2004). 
Lyophilized fluorescein was deposited on the lower conjunctival fornix by stripping the 
lyophilisate off the carrier in a wiping motion. The fluorescein dose was 68 μg in studies 1 
and 3, administered as a single eye drop (40 μL) or as lyophilisate. In study 2, a triple dose 
(204 μg) of fluorescein was given as a single lyophilisate application to one eye or as three 
conventional eye drops containing 68 μg in 40 μL each to the fellow eye, applied at 15-min 
intervals (0, 15 and 30 min) to avoid extensive immediate loss of the dose due to overflow. 
The rationale for the 204-mg dose in study 2 was to examine whether a three-fold higher 
single dose could be delivered into the eye when administered as a lyophilisate.  
2.1.2 Measurements and Variables 
 
Fluorescein concentrations in the cornea and anterior chamber were measured non-
invasively by fluorophotometry (Fluorotron Master II, Ocumetrics, Palo Alto, CA, USA). 
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Measurement times were as follows: study 1, prior to the first dose and every 2 min up to 30 
min after dosing; study 2, prior to the first dose and 15, 30, 45, 60, 120, 180, 240, 300, 360, 
420 min after dosing; study 3, prior to the first dose and 15, 30, 45, 60, 120, 180 min after 
dosing.  
 
 
2.2 Clarithromycin Data 
2.2.1 Clinical Studies and Ethical Conduct 
 
A total of twelve healthy Caucasian volunteers (7 men and 5 women; 19 – 40 years; 47.3 – 
85.2 kg body weight; 157-182 cm body height) were enrolled into a single centre, open, 
randomized steady-state clinical study, which had been approved by the Ethics Committee 
of the Ministry of Health Clinic Hospital of the Republic of Moldavia, Chisinau, Republic of 
Moldavia. The study was conducted according to the revised version of the Declaration of 
Helsinki. All participants gave their written informed consent. Volunteers were non-smokers 
or ex-smokers between the age of 19 and 41 (mean and SD 28 ± 8) years, their weight was 
between 45.1 and 86.1 kg (66.5 ± 11.8 kg), body height ranged between 150.0 to 186.0 cm 
(168.4 ± 9.7 cm). Participants were judged to be healthy as based on medical history, vital 
signs, complete physical examination, neurological assessment, and 12-lead 
electrocardiogram, clinical chemistry, hematology, urinalysis, and virological tests.  
Each subject took an oral dose of 500 mg clarithromycin every 12 h for four consecutive days 
(a total of seven doses, each single dose was 500 mg per 10 mL of clarithromycin suspension 
equivalent to 500 mg clarithromycin, Klacid, Abbott B.V., Hoofddorp, Netherlands). Subjects 
took the drug in the fasting state with 240 mL low-carbonated calcium-poor mineral water. 
After each administration the subjects lay in bed for at least 3 hours. Consumption of alcohol 
was prohibited starting at 2 days, beverages or foods containing methylxanthines starting at 
2 days, and grapefruit products starting at 7 days predose, respectively. From approximately 
8 hours before until approximately 4 hour after each morning dose and from approximately 
2.5 hours before until approximately 3 hours after each evening dose no food was allowed. 
Identical low fat food was given on all study days. No fluid intake from 1 hour before until 2 
hours postdose (with exception of the fluid for study drug administration) was allowed. 
Thereafter, 120 mL of low-carbonated calcium-poor mineral water (room temperature) was 
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given every hour until 11 hours after morning administration. No extensive fluid intakes 
(>120 mL/hour) were allowed during nights.  
 
2.2.2  Measurements and Variables 
 
Blood samples were collected for quantification of clarithromycin and its 14(R)-hydroxyl 
metabolite immediately before administration and 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 
5.5, 6, 8, and 12 h after the first, third and seventh dose. Additionally, one sample each was 
taken immediately prior to the fifth and sixth dose. Plasma samples were analyzed by a 
validated LC-MS/MS assay at the institute of Biomedical and Pharmaceutical Research, 
Nürnberg-Heroldsberg.  
Briefly, plasma samples (0.1 mL) were precipitated by addition of 200 µL of acetonitrile 
containing the internal standard. After thorough mixing, the samples were centrifuged for 5 
minutes at 3,280 g at approximately +4 °C, and the supernatant was diluted (1:1) with 
buffer. 15 µL of each sample were chromatographed on a reversed-phase column (Waters 
Symmetry C-8), eluted with an isocratic solvent system consisting of ammonium acetate 
buffer and acetonitrile (65/35,v/v, pH 4) and monitored by LC-MS/MS with a single reaction 
monitoring (SRM) method as follows: Precursor  product ion for clarithromycin m/z 749  
m/z 158, m/z 765  m/z 158 for 14(R)-hydroxy-clarithromycin and m/z 838  m/z 679 for 
internal standard, all analyses were in positive mode. Under these conditions clarithromycin, 
14(R)-hydroxy-clarithromycin and the internal standard were eluted after approximately 1.8, 
0.8 and 2.0 minutes, respectively. The MacQuan software (version 1.6, PE Sciex, Thornhill, 
Ontario, Canada, 1991 - 1998) was used for evaluation of chromatograms.  
Plasma samples were measured against a plasma calibration row prepared by adding the 
defined amounts of standard solution to drug-free human plasma. Spiked quality controls 
(SQC) were prepared for determination of interassay variation by the addition of defined 
amounts of the stock solution or the spiked control of higher concentration to defined 
amounts of tested drug-free human plasma. There was no interference observed in plasma, 
for clarithromycin, 14(R)-hydroxy-clarithromycin or the internal standard. Weighted linear 
regression (1/ concentration2) was performed for calibration. Linearity of the calibration 
curve could be shown in human plasma between 0.00992 µg/mL and 3.98 µg/mL for 
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clarithromycin and between 0.0101 and 4.04 µg/mL for 14(R)-hydroxy-clarithromycin. Lower 
limits of quantification were identical with the lowest calibration levels.  
The inter-day precision and the analytical recovery of the spiked quality control standards of 
clarithromycin in human plasma ranged from 3.0 to 4.4 % and were 99.9 % (3.07 µg/mL), 
100.4 % (1.02 µg/mL), 100.3 % (0.0941 µg/mL) and 100.9 % (0.0267 µg/mL), respectively. 
The inter-day precision and the analytical recovery of the spiked quality control standards of 
14(R)-hydroxy-clarithromycin in human plasma ranged from 6.3 to 6.8 % and were 100.1 % 
(3.04 µg/mL), 97.2 % (1.01 µg/mL), 95.5 % (0.0930 µg/mL) and 96.8 % (0.0264 µg/mL), 
respectively. 
 
 
2.3 Dextromethorphan Data 
2.3.1 Clinical Studies and Ethical Conduct 
 
Data from a total of fifty healthy Caucasian male volunteers from 3 cocktail interaction 
studies were available for this evaluation; 16 in study A, 11 in study B, and 11 in study C 
(Klaassen et al. 2008; Tomalik-Scharte et al. 2009). Briefly, all studies were approved by the 
ethics committee of the Medical Faculty of the University of Cologne, Germany, and were 
conducted according to the revised version of the Declaration of Helsinki and corresponding 
European and international guidelines. All participants gave their written informed consent. 
The data evaluated in this study is from the reference period where each subject received a 
single oral dose of 30 mg dextromethorphan hydrobromide (one capsule of Hustenstiller-
ratiopharm, ratiopharm, Ulm, Germany). Data from two subjects carrying rare CYP2D6 
alleles were excluded from this evaluation (see below) and therefore 36 male subjects (18 – 
49 years; 60 – 101 kg body weight; 171 – 195 cm body height) were enrolled in this 
evaluation. 
 
2.3.2 Measurements and Variables 
 
Blood samples were collected for quantification of dextromethorphan and dextrorphan as 
follows:  
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Study (A) immediately before administration and 0.17, 0.5, 0.75, 1.0, 1.33, 2.0, 3.15, 4.25, 
5.25, 6.0, 8.0, 10.0, 11.95, 14.0, 24.0 h after dosing;  
Study (B) immediately before administration and 0.17, 0.33, 0.50, 1.0, 1.33, 1.67, 2.0, 2.5, 
3.25, 3.95, 4.5, 5.25, 7.00, 10.00, 12.0, 16.0, 24.0 h after dosing;  
Study (C) immediately before administration and 0.17, 0.33, 0.50, 0.75, 1.00, 1.33, 1.67, 2.0, 
2.5, 3.25, 3.95, 4.13, 4.25, 4.5, 4.75, 5.0, 5.5, 6.5, 8.0, 10.0, 12.0 h after dosing. 
 
For quantification of dextromethorphan and dextrorphan in urine, urine samples were 
collected periodically and the volume and pH-value of each period were measured. The 
urine sampling schedules were:  
Study (A) immediately before administration and 0-2, 2-4, 4-6, 6-8, 8-12, 12-16 und 16-24 h 
after dosing;  
Study (B) immediately before administration and, 0-6 und 6-12 h after dosing;  
Study (C) immediately before administration and, 0-2, 2-4, 4-6, 6-8, 8-12 h after dosing.  
 
Plasma and urine samples were analyzed at the Institute of Pharmacology, University of 
Cologne, according to a previously published validated LC-MS/MS method (Wyen et al. 
2008). The lower limits of quantification were 0.103ng/mL for dextromethorphan and 
0.101ng/mL for dextrorphan. Precision ranged from 3.2 to 7.8% for dextromethorphan, and 
from 4.7 to 9.2% for dextrorphan, while accuracy was 101.8–102.9%, and 97.4–99.5% for 
dextromethorphan and dextrorphan, respectively. 
 
Genotyping Assays: All polymerase chain reaction amplifications were carried out in 50 μl 
reaction mixtures containing 100 ng of genomic DNA, 1x buffer, 2.3 mM MgCl2, 0.5 μM of 
each primer, 0.8 mM of dNTPs, and 2.5 U HotStarTaq DNA Polymerase (Qiagen). After 
purification, polymerase chain reaction products were sequenced using the BigDye 
Terminator Cycle Sequencing Ready Reaction Kit v2.0 (Applied Biosystems, Foster City, CA). 
Sequencing analysis was performed on a Genetic Analyzer 3100 capillary sequencer (Applied 
Biosystems) and pairwise sequence alignments were done with GenBank sequence 
NM_000927 using MT Navigator PPC and Edit View software (Applied Biosystems). 
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2.4 Phenprocoumon Data 
2.4.1 Clinical Studies and Ethical Conduct 
 
A total of 278 Caucasian patients (173 male/105 female; mean age 68.6± 11 (range: 26 -90) 
years; mean body weight 81± 15 (range: 46 – 132) kg; mean body mass index 27.9± 4.6 (range: 
16.7 – 45.6) kg/m2) were enrolled in a multi-centre steady-state, clinical study that had been 
approved by the Ethics Committee of the University of Tübingen, University of Cologne and 
University of Mannheim. The study was conducted in accordance with the Declaration of 
Helsinki and the relevant European and international guidelines after obtaining written 
informed consent from all participants. All subjects were on stable dosing regimen 
(mean±SD: 13.62± 5.75 (range: 3.75 - 37.50) mg/week)  of phenprocoumon (Marcumar®, Roche, 
Grenzach-Wyhlen, Germany; or Falithrom®, Hexal, Holzkirchen, Germany) for at least four 
weeks before inclusion date to ensure steady state achievement. Some minor modifications 
of the phenprocoumon dose during the last four weeks were present in many individuals. 
Information on phenprocoumon past dosage schedules and aim of the therapy was gathered 
from patients’ anticoagulation documentations. Furthermore, information was documented 
regarding the presence of co-medication and other diseases, previous occurrence of 
bleeding in the last 30 days (if any), consumption of caffeine, alcohol, and cigarettes. 
 
2.4.2 Measurements and Variables 
 
A single blood sample was collected just before the next phenprocoumon (PPC) dose from 
each patient. An aliquot for genetic analysis was frozen immediately at-20 °C. The aliquot for 
quantification of PPC concentrations was centrifuged (1992 x g, 15 min, 4 °C) and the 
obtained plasma samples were kept under -20 °C prior to LC-MS/MS analyses at the Institute 
of Pharmacology, University of Cologne. 
Phenprocoumon was purchased from HoffmannLa Roche, Grenzach-Wyhlen, Germany. The 
metabolites 4´-, 6-, and 7-OH phenprocoumon were synthesized in the Department of 
Chemistry, University of Konstanz, Germany. The internal standard warfarin was obtained 
from Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany. Ammonium acetate ( 97%) and 
acetic acid (100%) were purchased from Carl Roth GmbH & Co, Karlsruhe, Germany. 
Acetonitrile was purchased from Merck KGaA, Darmstadt, Germany. All solvents used for LC-
MS/MS were of chromatographic grade. 
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The liquid chromatography–tandem mass spectrometry system consisted of an Agilent 1200 
LC Binary SL Pump (Agilent, Waldbronn, Germany), fitted with a tempered tray (5°C) of a CTC 
PAL Autosampler and an Agilent 1200 TCC SL column oven (30°C), coupled to a triple 
quadrupole mass spectrometer (API 5000 with QJetTM Ion Guide, Applied Biosystems, Foster 
City, CA) with an electrospray ionization source with positive polarity (ESI+). N2 was used as 
sheath, auxiliary and as collision gas. The system was operated in the multiple reaction 
monitoring (MRM) mode. Analyst software (version 1.4.2, Applied Biosystems) was applied 
to control the instrument operation as well as the data acquisition and analysis. After 
thawing, 400 μl of acetonitrile (100%) and 20 μl of 1000 ng/ml warfarin (internal standard) 
was added to 200 μl plasma. Thereafter, the sample was vortex mixed and centrifugated at 
14,000 x g for 10 min). Then, the supernatant was transferred into an LC-MS-vials and 40 μl 
were injected into the liquid chromatography-tandem mass spectrometry system. The 
parent and its metabolites were not analyzed enantiospecifically and thus measured 
concentrations represent the sum of both enantiomers. For chromatographic separation, an 
Aquasil C18 column (100 × 3 mm, 5 μm, Thermo Electron, Runcorn, UK) was used at a 
constant flow rate of 0.5 ml/min. The mobile phases were 10 mM ammonium acetate (pH 
3,5) in 0.1% acetic acid (A), and 100% acetonitrile (B). The gradient of B was as follows: 10% 
(0–0.5 min), 10% (0.5–1 min), 50% (1–6 min), 50% (6–6.5 min) and 10% (6.5-7 min).  
Calibration curves were developed by spiking 100 L blank plasma with 100 µL of 
phenprocoumon and its metabolites using six different concentrations in the range of 200-
12500 ng/ml phenprocoumon and 10-625 ng/ml (hydroxy metabolites), respectively. The 
following parent/product ions were monitored: phenprocoumon M+H+ m/z 281  203, 4`-
hydroxyphenprocoumon M+H+ m/z 297  204, 6-hydroxyphenprocoumon M+H+ m/z 
297  220, 7-hydroxyphenprocoumon M+H+ m/z 297  220, and warfarin M+H+ m/z 
309  163. Phenprocoumon, 4`-hydroxy-, 7-hydroxy-phenprocoumon and warfarin were 
eluted at 3.45, 2.35 2.61, and 3.18 min, respectively. The metabolite 6-OH PPC could not be 
measured because it failed to meet stability criteria. Quantification of analytes was carried 
out using peak area ratios of the analyte and internal standard. The lower limits of 
quantification were 200 ng/mL for phenprocoumon, and 10 ng/mL for the 4`- and 7-hydroxy 
metabolites. The method was fully validated according to international guidelines. Precision 
ranged from 2 to 13% for phenprocoumon, and from 2 to 15% for 4`- and 7-OH PPC, while 
accuracy was 1 to 15%, and 1 to 20% for phenprocoumon and 4`-and 7-OH PPC, respectively.  
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The value of International Normalized Ratio (INR) of prothrombin time was determined by 
the respective routine methods of the Institute for Clinical Chemistry of the University 
Hospital of Cologne and the Clinical Chemistry Laboratory in Tübingen and Mannheim, and 
further external laboratories. 
Genotyping Assays: Genotyping was done after isolation of genomic DNA from whole blood 
samples by the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). CYP2C9 genotyping 
was carried out for CYP2C9 *1, * 2, and *3 alleles through specific hybridization probes using 
real-time polymerase chain reactions. Determination was done by the LightCycler-CYP2C9 
Mutation Detection Kit (Roche Diagnostics GmbH, Mannheim, Germany) using a LightCycler 
Instrument (Roche Diagnostics GmbH, Mannheim, Germany). 
The genotyping of the VKORC1 gene was carried out by direct sequencing of exons 1, 2 and 3 
and their introns 1 and 2 and parts of the 5’- and 3’-untranslated regions. Appropriate 
primers for primary PCR were selected. After PCR the products were purified by vacuum 
filtration (MANU 3050, Millipore, Molsheim, France). Afterwards sequencing PCRs were 
carried out with the BigDye Terminator Cycle Sequencing Kit v1.1 (Applied Biosystems, 
Darmstadt, Germany) and appropriate oligonucleotides. After purification of the sequencing 
products using Sephadex G50 (Sigma Aldrich, Taufkirchen, Germany) the samples were 
analysed on a Genetic Analyzer Prism 3100 (Applied Biosystems, Darmstadt, Germany). 
 
 
2.5 Data Analysis 
2.5.1 Software 
 
The noncompartmental evaluation was performed with the WinNonlin software (version 
5.0.1, Professional Edition, Pharsight, Mountain View, CA, USA). Maximum drug 
concentration (Cmax) and time of maximum concentration (tmax) were taken from the raw 
data, and the area under the curve from time 0 to the last sampling time tAUC0  was 
calculated using the loglinear trapezoidal rule. 
For the purpose of developing population models, all compartmental PK/PD analyses and 
simulations were performed using the software NONMEM version V, or VI (NONMEM 
software version 1.1, NONMEM Project Group, University of California at San Francisco, 
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1998). The first-order conditional estimation algorithm (FOCE INTER), assuming interaction 
between the residual error and the interindividual error, was used in all cases. Disposition 
kinetics of the developed models was parametrized in terms of the apparent clearance and 
apparent volume of distributions. 
The software S-Plus (S-Plus version 8.0, Insightful Corporation, Seattle, WA, USA) was used 
for model diagnostic purposes and for exploration of possible covariate relationships 
(Mandema et al. 1992).  
 
2.5.2 Model Justifications 
 
Model derivation and justification was guided through the following criteria whatever 
applicable: 
- A difference in the objective function value (ΔOFV) generated via NONMEM was used 
to carry out comparisons between any two models. A ΔOFV of 3.84 (approximate χ2-
distribution) for an additional parameter was used for determining statistical 
significance (P < 0.05) of the difference between two models. 
- Visual inspection of goodness-of-fit plots including individual and population 
predictions, residual plots, individual curve fitting. 
- Physiological plausibility and statistical precision of parameter estimates and 
variability estimates.  
- The 95% confidence intervals for the parameter estimates should not include zero or 
unity. Confidence intervals were estimated for each population parameter as θp ± SE 
× Z, where θp is the estimate population parameter, SE is its associated standard 
error, and Z is the interval coefficient for a standard normal distribution (Z=1.96 for a 
95% confidence interval). 
- The final model performance was also justified by simulating concentration time 
profiles for 1000 subjects having different key parameters like different alleles or 
variants. 
- The predictive performance was evaluated by visual predictive checks to assess, 
whether a model described the central tendency and variability of the observations 
adequately. The median, 5th and 95th percentiles of the concentration time curves 
were calculated by validated Perl scripts (Bulitta et al. 2007) (Active Perl, version 
5.10.0; ActiveState, Vancouver, Canada).  
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2.5.3 Covariate Analyses 
 
Multiple activities were performed to identify the kind of relationship between available 
covariates and individual pharmacokinetic parameter can produce the best description of 
the data. These relationships were first explored by visual inspection of plots of individual 
parameters versus covariates. Formal testing was then performed by inclusion of covariates, 
one by one, in the NONMEM model. A significance level of p ≤ 0.05 was used in the forward 
inclusion steps to generate the full model. This model was then reduced by eliminating 
covariate-parameter relationships, one by one, and only those covariate effects that were 
significant at the p ≤0.001 level were retained in the final model (Mandema et al. 1992). 
 
2.5.4 Statistical Models 
 
The interindividual variability was modelled with an exponential error model for all 
pharmacokinetic parameters, with stepwise cumulative inclusion of respective error terms 
according to the equation: 
θj = θp · exp (ηθj) 
where θj is the estimate for a pharmacokinetic parameter in the jth individual as predicted 
by the regression model, θp is the population mean of the pharmacokinetic parameter, and 
ηθj represents the random variable with zero mean and variance ω
2 that distinguishes the jth 
individual pharmacokinetic parameter from the population mean value predicted by the 
regression model.  
 
The intraindividual variability (Residual variability) was quantified by teasing out different 
models including: 
- Additive model: Cij = Cpij + ε1,ij 
- Proportional model: Cij = Cpij + ε1,ij ∙ Cpij 
- Exponential model: Cij = Cpij · exp (ε1,ij) 
- Combined model: Cij = Cpij + ε1,ij ∙ Cpij +  ε2,ij 
where Cij is the observed concentration in individual i at time j, Cpij is the model 
predicted concentrations in individual i at time j, and ε(x),ij describes the independent, 
identically distributed statistical errors with mean 0 and variance σ2. 
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2.5.5 Fluorescein Data Analysis 
 
Raw data from the original studies have been published previously (Dinslage et al. 2002; Lux 
et al. 2003; Steinfeld et al. 2004), but no pharmacokinetic methods have been applied to 
these data. For all pharmacokinetic calculations, baseline correction of the original data was 
done to account for autofluorescence of ocular tissues by subtracting the observed 
fluorescence prior to administration from the values after administration. 
A nonparametric evaluation of ocular pharmacokinetics parameters was performed with 
WinNonlin to obtain maximum fluorescein concentrations (Cmax) in the cornea and anterior 
chamber, and the area under the time-concentration curve tAUC0 . It was not possible to 
calculate the extrapolated area under the curve to infinity or the elimination rate constants 
for many subjects for both formulations due to the scatter of data around the corrected 
baseline and the fact that none of the studies covered the entire concentration vs. time 
profile of fluorescein. Point estimates of the ratios of lyophilisate over eye drops for tAUC0  
and Cmax including the respective 90% confidence intervals were calculated using standard 
bioavailability methods after log-transformation of the data.  
Population model building procedures: Compartmental population pharmacokinetic 
parameters of fluorescein were estimated using NONMEM V. The ocular pharmacokinetic 
model of fluorescein was developed in two consecutive steps; the first step was to find a 
model for the eye-drop formulation only, and in the second step this was applied to estimate 
differences in pharmacokinetic parameters due to formulation effects. The model was 
parameterized in terms of clearances and distribution volumes using the PREDPP subroutine 
ADVAN 5 supplied in NONMEM. Covariate (e.g., sex, age, and body weight) data sets were 
not complete for all subjects and therefore they were not considered for the sake of model 
development; they are, however, not expected to have a major impact on ocular 
pharmacokinetics. 
In the first step used to evaluate the eye-drop data, the absorption rate constant was fixed 
at a high value (i.e., 1,000/h). This assumption was made because the data indicated 
immediate drug absorption and did not support the estimation of an absorption process. 
The bioavailable fraction was assumed to be unity for this formulation. Initially an attempt 
was made to fit all fluorescein concentrations, for all subjects, in the cornea and anterior 
chamber to a previously described two-compartment open model (Coakes and Brubaker 
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1979; Mishima 1981). Because no adequate fit could be achieved with this model, a three-
compartment model was chosen. In the second step, where lyophilisate data were to be 
evaluated, the apparent intercompartmental clearances, apparent volumes of distribution, 
and the apparent total clearances were fixed to the estimates obtained for the eye-drop 
data set, allowing only the relative bioavailability fraction and the absorption rate constant 
for the lyophilisate preparation to be estimated. This procedure is justified because these 
parameters are principally related to the physicochemical properties of fluorescein itself and 
not to the formulation. 
Statistical model: Interindividual variability was modelled with an exponential error model. 
Residual variability was expressed using two separate error terms for the cornea and the 
anterior chamber. Each residual model was modelled using an additive model, a 
proportional model, or a combination of both. 
 
 
2.5.6 Clarithromycin Data Analysis 
A noncompartmental evaluation of clarithromycin pharmacokinetics was performed with 
WinNonlin to obtain maximum drug concentrations (Cmax) in plasma, the Cmax time (tmax), 
apparent clearance and volumes of distributions parameters and the area under the time-
concentration curve 0AUC . 
Population model building procedures: A total of 624 samples of clarithromycin and 624 
samples of its 14-(R) hydroxyl metabolite from 12 subjects were co-modelled using 
NONMEM V. The model was specified as a set of differential equations using the ADVAN6 
subroutine. 
A one-compartment open model with first-order absorption with or without a lag time was 
tested to describe clarithromycin plasma concentration profiles after the first dose with first-
order elimination. A compartment for the hydroxyl metabolite was included. Absorption 
behaviour could not be described properly by first-order absorption; therefore a single 
phase Weibull function (Zhou et al.) was tested. This function was coded as: 
 
WB = 1- exp (-(kw*Tw)
λ
) 
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where, kw is the absorption rate constant, Tw is the time after the previous dose and λ is the  
shape parameter (Petricoul O 2007). This model appropriately described the absorption 
phase while using more complicated input models was not successful. 
The distribution kinetics of the parent and metabolite was assumed to follow linear 
pharmacokinetics. This model was selected as a base structural model. Clarithromycin 
clearance was modelled with linear and/or nonlinear kinetics including a Michaelis-Menten 
model. Elimination of the metabolite was assumed to follow linear pharmacokinetics. 
Individual body weights were related to a standard weight, i.e. 70 kg, and used as covariate 
for apparent volumes of distribution and total clearances parameters of clarithromycin and 
its metabolite as: 
)70/(
)70/( 75.0
kgBWVV
kgBWCLCL
i
i




 
where CLi  and Vi  stand for individual apparent total clearance and distribution volume 
respectively, BW is the individual body weight expressed in kg; 

CL  and 

V represent  mean 
clearance and mean volume of distribution, respectively, of typical subjects weighing 70 kg 
(Anderson et al. 1997). 
Statistical model: An exponential-variability model was included to describe between 
subject variability for all pharmacokinetic parameters, with stepwise cumulative inclusion of 
respective error terms.  
Two separate residual variability terms were included in the model: one for clarithromycin 
and the second for its hydroxyl metabolite. Each residual model was modelled using an 
additive model, a proportional model, or a combination of both. 
 
Simulation: Based on the final parameter estimates of the selected population model, 
simulations were performed using NONMEM V to predict the concentration profiles for 
multiple doses of 250, 500, 750, or 1000 mg twice daily. The simulation was done for periods 
sufficient for achieving theoretical steady-state. For these doses, areas under the plasma 
curves of the free drug form (fAUC0-24), the fAUC0-24 / MIC ratio and the probability of 
attainment the pharmacodynamic target fAUC0-24 / MIC > 35 h (Craig et al. 2002; Tessier et 
al. 2002) across various MIC values were calculated in steady-state, assuming no significant 
change in protein binding (Peters and Clissold 1992; Traunmuller et al. 2007).  
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2.5.7 Dextromethorphan Data Analysis 
 
Among the participants of the study, there were two subjects carrying one *9 allele each and 
one carrier of a *10 s allele. Data from these three subjects were excluded from the 
evaluation as the low allele frequencies preclude estimation of population parameters. 
Noncompartmental evaluations were performed using WinNonlin to derive model-
independent pharmacokinetic parameters of dextromethorphan and dextrorphan in plasma.  
Population model building procedures: All observed plasma and urine concentrations of 
dextromethorphan and dextrorphan from 47 volunteers were analysed simultaneously using 
NONMEM version VI. Models were specified in sets of differential equations using the 
ADVAN6 subroutine. 
As a starting point, a four-compartment open model was tested to describe the whole data. 
Each compartment represents each site of measurement (i.e., two compartments each 
[plasma and urine] for dextromethorphan data and two compartments for dextrorphan 
data). The absorption process was assumed to follow first-order input kinetics. A first-order 
absorption rate constant with and without a lag time was explored. Disposition processes for 
both substances were assumed to follow linear kinetics. For the purpose of semimechanistic 
modeling, dextromethorphan was assumed to being converted totally to dextrorphan. This 
metabolic clearance was described as follows: 
 
CLm = CLb + CLCYP2D6 
 
where CLm is the total apparent clearance of dextromethorphan describing the 
biotransformation of dextromethorphan to dextrorphan, CLb  is the basic value for 
dextromethorphan metabolic clearance that is not subject to CYP2D6 allelic activity, CLCYP2D6 
is the metabolic clearance due to CYP2D6 activity and was specified as follows: 
CLCYP2D6 = n*1 * CL*1 + n*2 * CL*2 + n*42 * CL*41 
 
where n*x and CL*x, are the number of alleles observed and metabolic clearance values 
attributable to the respective allele. This model was selected as a basic structural model for 
further model building activities.  
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The activity of *4, *3 and *6 alleles was set to zero as they are inactivating mutations (Marez 
et al. 1997). Clearance of dextromethorphan in individuals who are homozygous for these 
alleles was assumed to reflect the non-CYP2D6 mediated clearance. Hence, the study 
evaluated the activity of 2D6*1, 2D6*2 and 2D6*41 alleles, which have recognized as true 
variants influencing dextromethorphan metabolism activity in vivo (Marez et al. 1997; 
Sachse et al. 1997; Cai et al. 2007; Sistonen et al. 2007). In addition to CYP2D6 
polymorphisms, age, urine pH, and weight as covariates were considered during model 
building for their impact on pharmacokinetic parameters. An  allometric model was used for 
weight, while exponential and combined models were used to centre the age effect to the 
mean or the median age values (Holford, N 2002). 
Statistical model: An exponential interindividual variability model was included for all model 
parameters forward and backward step by step interchangeably. Four residual-error models 
were added, one for each data type (i.e., a separate residual-error model for plasma parent 
data, another for plasma metabolite data etc.). Each residual model was modelled using an 
additive model, a proportional model, or a combination of both. 
 
 
 
2.5.8 Phenprocoumon Data Analysis 
Data analysis was performed using the nonlinear mixed-effect software in NONMEM version 
VI using the PRED routine and the first-order conditional estimation method with 
interactions. Covariates were tested and forward included in the model in a stepwise 
manner starting with the covariate that resulted in the greatest reduction in the OFV. This 
procedure was repeated until no significant drop was obtained in the objective function 
value.  
The CYP2C9 [VKORC1] polymorphisms, age, weight, and sex were considered during PK [PD] 
model building. In a sequential manner, final parameter estimates obtained from the 
pharmacokinetic model were used for pharmacodynamic model building. This approach has 
been shown to be computationally faster and can provide less biased PD estimates than the 
simultaneous analysis approach (Zhang et al. 2003a; Zhang et al. 2003b). 
Pharmacokinetic model building procedures: All plasma concentrations of phenprocoumon 
and its 4'- and 7-hydroxy metabolites were analyzed simultaneously. Previous 
pharmacokinetic analysis of phenprocoumon in plasma after oral administration reported 
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the adequacy of an open one-compartment model (Masche et al. 1999). Thus, a three-
compartment open model, one compartment for phenprocoumon concentrations and the 
other two compartments for 4'- and 7-hydroxy metabolite concentrations, was assumed to 
describe the whole data. Because only one sample was observed per subject, absorption 
process could not be evaluated. Furthermore, these observations were obtained at one 
sampling time at steady state and that was the same for everyone, therefore a meaningful 
apparent volume of distribution could not be obtained. Hence, the model was developed to 
describe the steady state concentration independent of volume of distribution of the parent 
and its metabolites. The input process was modelled as a constant infusion (dose/dosage 
interval) and just assumes all concentrations are at steady state. The model was 
parameterized in terms of clearance. 
Pharmacodynamc Model building procedures: The calculated individual predictions of the 
parent from the final pharmacokinetic model were used to develop the pharmacodynamic 
model. A simple linear model was considered to describe the variability in INR values in this 
population. The VKORC1 polymorphisms, sex, body weight, age, and mass body index were 
evaluated as covariates on the parameters reflecting the patient´s sensitivity to 
phenprocoumon.  
Statistical model: Exponential interindividual variability terms were assumed and evaluated 
for PK and PD model parameters during model development processes. Because the model 
cannot separate the residual variability from interindividual variability based on one 
observation per subject (Ette et al. 1995), residual variability terms had to be fixed to small 
values. For the PK-model, three additive error terms were used to describe the residual 
variability for the parent and metabolites data and their values were fixed to the lower limits 
of the assay quantification. For the PD model, an additive residual error for INR was used 
and fixed to a priori information of 0.0325 (Hamberg et al. 2007). Plausibility of these fixed 
values was tested by replacing it with higher and lower values.  
 
Simulation: Two simulations were executed with use of NONMEM to visualize the model 
performance using the final PK parameter estimates. The first simulation was run to simulate 
steady state plasma concentration profiles of the parent drug for male subjects having 70 kg 
body weight and being 45 years old but with different CYP2C9 features. The second 
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simulation was performed to show the effect of VKORC1 variants in determining the INR at 
steady state.  
 
Finally and based on final model estimates, and assuming a target INR of 2.5 is clinically 
desirable, the required maintenance dose of phenprocoumon was calculated for 45 years 
old male subjects with 70 kg body weight, possessing different combinations of CYP2C9 and 
VKORC1 polymorphisms. 
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3 RESULTS 
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3.1 Fluorescein 
All subjects were included in a noncompartmental and in a compartmental ocular 
pharmacokinetic analysis of fluorescein from eye drops and lyophilisate forms. The raw data 
are scattered, which can be attributed to methodological limitations of ocular 
fluorophotometry. Plots of fluorescein concentrations in the cornea and in the anterior 
chamber after baseline correction for both formulations are given in Figure 6.  
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Figure 6: Florescein concentrations (ng/mL) in the cornea and anterior chamber (raw data) 
 
These plots show that the original data are quite scattered. Despite this limitation, the 
noncompartmental pharmacokinetic parameters clearly show a higher extent of ocular 
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bioavailability of fluorescein from lyophilisate relative to the eye-drop formulation. Values of 
tAUC0  and Cmax for both formulations and their ratios are given in Table 2.  
 
Table 2: Non-compartmental pharmacokinetics of fluorescein following administration of 
lyophilisate and eye drops 
 Study Dose 
(µg) 
No. of 
subjects 
Drops 
(mean  ± SD) a 
Lyophilisate 
(mean  ± SD) a 
Ratio  
(90% CI) 
Cornea    AUC0
t 
(hr/ml/ng) 
 1 68 10 48  ±  2.77 538  ±  2.11 11.3  (5.7 – 22.0) 
 2 204 22 90  ±  2.22 566  ±  3.78 6.3  (3.9 – 10.2) 
 3 68 12 9  ±  3.10 133  ±  3.04 14.6  (8.7 – 24.7) 
    Cmax 
(ng/mL) 
 1 68 10 601  ±  2.67 3514  ±  1.92 5.9 (2.9 – 11.8) 
 2 204 22 77  ±  3.23 968  ±  6.02 12.5 (6.6 – 23.8) 
 3 68 12 12  ±  3.04 243  ±  6.24 19.9 (10.2 – 38.9) 
Anterior 
chamber 
   AUC0
t 
(hr/ml/ng) 
 1 68 10 1.3  ±  2.84 11  ±  2.12 8.9 (4.9 – 16.4) 
 2 204 22 14  ±  1.98 66  ±  2.46 4.7 (3.10– 7.0) 
 3 68 12 3.0  ±  2.19 22  ±  1.70 6.9 (4.2– 11.23) 
    Cmax 
(ng/mL) 
 1 68 10 13  ±  2.17 80  ±  1.91 6.3 (3.3 – 12.1) 
 2 204 22 2.2  ±  3.20 30  ±  3.94 13.7 (8.0– 23.4) 
 3 68 12 4.1  ±  2.06 18  ±  2.59 4.3  (1.3 –14.1) 
a
 Data given as geometric mean ± standard deviation 
Sampling schedules were as follows: study 1: 0–30 min (15 observations); study 2: 0–420 min (10 
observations) study 3: 0–180 min (6 observations). AUC0
t
:  area under the concentration time curve up 
to the last observation time, Cmax: maximum observed concentration, ratio point estimate for ratio of 
lyophilisate over eye drops, CI confidence interval, and a Geometric standard deviation. 
 
Population kinetics indicated the superiority of the three-compartment model compared 
with two-compartment model based on individual and population predictions. This 
superiority was also confirmed by a marked drop in the objective function (∆ OFV= 2106). 
Blue print of the final model is given in Figure 7. 
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Figure 7: Blueprint of the final fluorescein population pharmacokinetic model. 
 A three-compartment model used to describe the transfer of fluorescein into and from the cornea and 
anterior chamber after topical administration of the drug as eye drops and lyophilisate. ka is the 
absorption rate constant, V1, V2, and V3 are the apparent volumes of distribution of fluorescein in the 
first, second and third compartments, respectively. Q1, Q2, and Q3 are the intercompartmental 
clearances and kel is the elimination rate constant. 
 
 
This model was described by the following parameters: ka is the apparent absorption rate 
constant, V1 is the apparent volume of distribution in the cornea, Q1 is the apparent 
intercompartmental clearance between cornea and anterior chamber, V2 is the apparent 
volume of distribution in the anterior chamber, CLtot is the apparent total clearance, Q2 is the 
intercompartmental clearance between anterior chamber and the third compartment, V3 is 
the apparent volume of distribution in the third compartment, and Q3 is the 
intercompartmental clearance between the third compartment and the cornea. Elimination 
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Fluorescein was assumed to be eliminated from the anterior chamber compartment with 
first order elimination rate constant, kel. 
 
 Visualisation of the population data shows that this empirical model could adequately 
describe fluorescein data in the cornea and anterior chamber (Figure 8a and 8b). Examples 
of typical individual predictions are given in Figure 9. Diagnostic plots of the final model for 
both formulations are given in Figure 10 and 11. These plots of the observed concentrations 
vs. the population-predicted concentrations show the reasonable distribution of original 
data around the line of unity. Final model specifications are given in Figure 12. The effect of 
the formulation type on the absorption rate could not be assessed because there were not 
enough data points early after administration of fluorescein, but it was possible to estimate 
an apparent absorption rate following administration of the lyophilisate. The relative 
systemic bioavailability of fluorecsein from lyophilisate was estimated to be about 3.7-fold 
higher (95% CI 2.9 – 4.5) than following administration of the eye drops. It should be noted 
that this estimate is based on ocular concentration vs. time profiles only, i.e., systemic 
availability via the ocular route was estimated; this does not take into account fluorescein 
lost by lacrimation and reaching the systemic circulation via conjunctival, nasal, or 
gastrointestinal routes. Population pharmacokinetic parameter estimates of fluorescein of 
the final models as well as the 95% confidence intervals are summarized in Table 3.  
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Figure 8a: Fluorescein concentrations in the cornea with the population model (solid lines).  
The eye drops in study #2 were administered at three different 68 µg doses given 15 min apart  
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Figure 8b: Fluorescein concentrations in the anterior chamber with the population 
model. 
The solid line is the population model. The eye drops in study #2 were administered at three different 
68 µg doses given 15 min apart.
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Figure 9: Individual predictions of fluorescein level in the cornea and anterior chamber in three 
subjects  
Open and closed cilcles represent raw data for eye drop and lyophilisate formulation, respectively 
Solid lines represent individual prediction model 
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Figure 10: Goodness-of-fit plots of the final model for the eye drop formulation. 
Plots show unity and zero lines in the right and left panels respectively. 
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Figure 11: Goodness-of-fit plots of the final model for the lyophilisate formulation  
Plots show unity and zero lines in the right and left panels respectively. 
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Table 3:  Ocular population pharmacokinetics of fluorescein 
a
 =Immediate absorption and a relative bioavailability of 1 were assumed for eye drops,
  
*
= relative standard errors of the estimated variance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Unit 
Point 
estimate 
95%CI 
Absorption rate constant (ka) for lyophilisate
a 1/hr 16.7 12.3 – 21.1 
Apparent volumes of distribution of fluorescein 
in the first compartments V1 
L 24.6 3.6 – 45.6 
Intercompartmental clearance Q1 L/hr 0.25 0.08 – 0.42 
Apparent volumes of distribution of fluorescein 
in the second compartments V2 
L 10.3 9.1 – 12.8 
Apparent total clearance CL L/hr 4.34 2.49 – 6.19 
Intercompartmental clearance Q2 L/hr 0.20 0.05 – 0.34 
Apparent volumes of distribution of fluorescein 
in the third compartments V3 
L 3.42 1.99- 4.85 
Intercompartmental clearance Q3 L/hr 0.54 0.20 - 0.87 
Relative bioavailability for lyophilisate (F)  3.7 2.9 – 4.5 
Interindividual variability in (Q1)  1.10 26.7 %* 
Interindividual variability in (CL)  0.34 8.6 %* 
Residual variability in cornea (CV %)  56.2 9.2% * 
Residual variability in anterior chamber (CV %)  52.0 5.7% * 
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Figure 12: Relevant NONMEM code of the final fluorescein model  
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3.2 Clarithromycin 
Data derived pharmacokinetic parameters estimated by non-compartmental analysis for 
clarithromycin and its hydroxymetabolite are given in Table 4. 
 
Table 4:  Noncompartmental pharmacokinetic parameters of clarithromycin and its 14(R)-
hydroxy metabolite 
 
Parameter 
 
1st dose 3rd dose 
7th dose 
(Steady state) 
C
la
ri
th
ro
m
yc
in
 
Cmax 
(µg/mL) 
2.49  ± 0.76 
(1.60 – 4.02) 
3.08 ± 0.82 
(1.77 – 4.80) 
3.57  ± 0.72 
(2.39 – 4.67) 
tmax 
(h) 
3.54 ± 0.99 
(1.50 – 5.00) 
3.54 ± 0.86 
(2.50 – 4.50) 
3.92 ± 0.87 
(2.00 – 5.50) 
AUC12h 
(h ·µg/mL) 
15.4 ± 5.1 
(9.4 – 29.7) 
21.8 ± 6.06 
(13.3 – 37.1) 
27.4 ± 6.76 
18.3 – 39.6 
t1/2 
(h) 
3.58 ± 0.71 
(2.83 – 5.47) 
4.26  ±  0.82 
(3.24 – 5.18) 
4.65 ± 1.04 
(3.34 – 7.75) 
kel 
(1/h) 
0.199 ± 0.033 
(0.127 – 0.245) 
0.168  ±  0.030 
(0.119 – 0.214) 
0.158 ± 0.032 
(0.109 – 0.207) 
Cav 
(µg/mL) 
NA NA 
2.29  ±  0.563 
(1.52 – 3.30) 
14
-O
H
-C
la
ri
th
ro
m
yc
in
 
Cmax 
(µg/mL) 
0.961 ± 0.254 
(0.545 – 1.32) 
1.11 ± 0.241 
(0.741 – 1.53) 
1.09 ± 0.225 
(0.721 – 1.57) 
tmax 
(h) 
4.33 ± 1.29 
(2.00 – 6.00) 
3.96 ± 1.03 
(2.50 – 5.50) 
4.71 ± 0.88 
(2.50 – 6.00) 
AUC12h 
(h ·µg/mL) 
7.19 ± 1.77 
(4.89 – 11.4) 
9.92 ± 2.45 
(6.95 – 14.1) 
10 ± 2.00 
(7 – 14.4) 
t ½ 
(h) 
38.07 ± 9.56 
(20.09 – 57.32) 
9.13  ±  2.96 
(5.67 – 14.81) 
8.89 ± 2.69 
(4.61 – 15.56) 
kel 
(1/h) 
0.105 ± 0.027 
(0.054 – 0.162) 
0.083  ±  0.026 
(0.047 – 0.122) 
0.084  ±  0.022 
(0.056 – 0.127) 
Cav 
(µg/mL) 
NA NA 
0.838  ±  0.166 
(0.584 – 1.20) 
Clarithromycin was administered as repeated oral doses of 500mg b.i.d.;  tmax is the time of maximum 
concentration (Cmax); t1/2 is the elimination half life; kel is the elimination rate constant; AUC12h is the 
area under the plasma concentration-time curve up to 12 hours; Cav is the average concentration at 
steady state; NA: not applicable. 
 
 
The absorption profiles of clarithromycin were best described by a Weibull absorption model 
that resulted in a marked improvement in the objective function value OFV (ΔOFV, - 86) 
compared with a first order absorption model. A plot of four individual plasma 
concentrations of clarithromycin versus time after the first dose is shown in Figure 13. This 
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figure shows how the Weibull model best described the absorption phase in comparison 
with a standard first-order absorption model. 
 
 
Figure 13: Visualisation of different absorption models of clarithromycin.  
Clarithromycin plasma concentration-time profiles for four individuals (upper figures) and population 
mean, N=12 (lower figure) after the first dose assuming linear elimination pathway. 
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Based on the multiple dose regimen of 500 mg, the apparent total drug clearance of 
clarithromycin (CLp) was found to decrease with time in a nonlinear fashion as shown by 
non-compartmental methods (Bulitta et al. 2003). As expected, a linear two-compartment 
model could not describe this nonlinearity. Addition of a nonlinear elimination pathway with 
Michaelis-Menten kinetics improved model fitting considerably (ΔOFV, - 252), however the 
overall nonlinearity was still not properly explained as this model was not able to capture 
maximum plasma concentrations of clarithromycin (Figure 14).  
 
 
Figure 14: Michaelis-Menten Model of clarithromycin.  
Clarithromycin fitting is on the left pane and its metabolite on the right with unity line. 
 
 
RESULTS 
 
62 
 
Finally, the inhibitory effect of clarithromycin on its apparent total clearance was modelled 
“mechanistically” by addition of a hypothetical inhibition compartment. The concentration 
of the parent drug was used to derive the extent of (reversible) inhibition in this 
compartment. Here, the total apparent clearance of clarithromycin (CLp) was split into two 
components. The first component was inhibited by the hypothetical clarithromycin 
concentration in the inhibition compartment (Cinhibt), whereas the second component was 
not affected by Cinhibt. The fraction of CLp that was not inhibited by Cinhibt was described as 
FCLp and its estimate allowed to range from zero (i.e. 100% inhibition) to unity (i.e. no 
clearance inhibition) (Plock et al. 2007). A transfer rate constant between parent and 
inhibition compartments ( ik ) in addition to the concentration in this compartment yielding 
50% inhibition of clarithromycin clearance (IC50) was included to explain the inhibition of 
clearance over time. This model is blueprinted in Figure 15 and its code specification is given 
in Figure 16. Inclusion of the inhibition compartment side by side to the drug model 
adequately described the nonlinear time-dependent auto-inhibition pharmacokinetics of 
clarithromycin. This model led to a significant improvement in the objective function 
compared to the Michaelis-Menten elimination model (ΔOFV, - 752).   
In the final model and for the available data, four between-subject variability terms were 
identified. In addition, residual additive error models resulted in the best model convergence 
compared with proportional and or combined error models. Pharmacokinetic parameter 
estimates of the final model are shown in Table 5. Standard goodness-of-fit plots of the final 
model of clarithromycin and its 14-(R) hydroxy metabolite are given in Figure 17. These plots 
suggested that the selected autoinhibition model adequately described both the plasma 
concentration time profiles of clarithromycin and its 14-(R) hydroxy metabolite 
simultaneously. The superiority of the inhibition model (final model) in comparison with the 
Michaelis-Menten model is given for three subjects in Figure 18. The visual predictive check 
of clarithromycin and its major metabolite indicated that the final model could predict the 
observations including the maximum plasma concentrations (Figure 19). The simulated 90% 
prediction interval closely reflected the observed plasma concentrations of clarithromycin 
and 14-(R) hydroxy clarithromycin.  
Concentrations of clarithromycin in the theoretical inhibition compartment as well as the 
extent of time course inhibition are shown in Figure 20. The plot suggested that inhibition 
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started rapidly and that the 500 mg b.i.d dose inhibited enzyme activity by approximately 
50% to 70 % of initial values during steady state.  
Based on the pharmacokinetic parameter estimates of the final model, the simulated 
medians for four dose levels, i.e., 250, 500, 750 and 1000 mg twice daily (Figure 21) 
suggested that the extent of auto-inhibition and the emerging changes in pharmacokinetics 
with time is much more pronounced for the higher doses. While for the 500 mg b.i.d 
standard dose no further increase of exposure occurs after the 2nd day of treatment, for a 
1000 mg b.i.d dose reaching steady state it is expected to take several days. AUC values at 
steady state for the 1000 mg b.i.d dose would exceed those for the 500 mg b.i.d dose by 3.6-
fold (Table 6). For the parent drug at steady state, the probability of achieving the target for 
pathogens having MIC value of 0.5 mg/L is 0 %, 43 %, 94 % and 100 % for the 250, 500, 750 
and 1000 mg doses, respectively (Table 6 and Figure 22).  
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WB= [ 1 – exp (– (kw · Tw)
 λ) ] h-1 
INH= FCLp + (1–FCLp) · (1 – Cinhibt / (IC50 – Cinhibt)) 
dAabs / dt = – WB ·Aabs 
dCp / dt = (WB · Aabs – Cp · CLp · INH)/Vp 
dCinhibt / dt = ki · Cp – ki · Cinhibt  
dCmet / dt = (Cp · CLp · INH – Cmet · CLmet)/Vmet 
 
Figure 15: Blueprint and differential equations of the final model 
 
WB is the Weibull absorption function from the gastrointestinal tract, Aabs is the amount of drug in the 
absorption compartment, kw is the absorption rate constant, Tw is the time after the previous dose and 
λ is the shape parameter of the Weibull function. Vp, Vmet, Cp and Cmet are the apparent volumes of 
distribution and plasma concentrations of clarithromycin and its hydroxy metabolite respectively; ki is 
the transfer rate constant between parent and inhibition compartments. Clarithromycin clearance 
(CLp) is inhibited based on the concentration in the inhibition compartment Cinhibt; and IC50 is the 
concentration in the inhibition compartment yielding 50% of maximum clearance inhibition of 
clarithromycin. INH is the overall inhibition parameter, FCLp is the fraction of the clearance not 
subject to inhibition and Cinhibt is the concentration of the clarithromycin effective in the inhibition 
compartment. CLmet is the apparent total clearance of 14(R)-hydroxy clarithromycin. 
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Figure 16: Relevant NONMEM code of the final clarithromycin model  
 
 
 
RESULTS 
 
66 
 
 
 
Figure 17: Goodness-of-fit plots for the final model of clarithromycin. 
 Plots include unity and zero lines for clarithromycin (left) and its hydroxyl metabolite (right) 
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Figure 18: Individual predictions of clarithromycin in 3 subjects. 
KIC-model= inhibition-compartment model (final model),  
MMK-model =Michaelis-Menten model
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Figure 19: Visual predictive check of clarithromycin model. 
Circles correspond to the actual plasma concentrations of clarithromycin (upper panel) and its 
metabolite (lower panel). Lines represent 5%, median and 95% percentiles 
75 
 
 
 
 
Figure 20: Inhibition compartment profiles. 
Upper panel: simulated clarithromycin concentration in the inhibition compartment for the 500 mg bid 
dose. 
Lower panel: autoinhibition of clarithromycin (%INH) INH is 100% if there is no inhibition, whereas 
maximal potential inhibition at high clarithromycin concentrations in the effect compartment would 
yield a value of 10% representing the non-inhibitable fraction of apparent clarithromycin clearance. 
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Figure 21: Simulated median plasma concentrations of clarithromycin.  
 
 
 
 
Figure 22: Probability of target attainment of free clarithromycin. 
Probability of free clarithromycin to achieve a target (i.e. fAUC24h / MIC >35 h) at steady state for 
various MIC values upon b.i.d. administration of the respective clarithromycin doses 
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Table 5: Population pharmacokinetic estimates of clarithromycin (500 mg b.i.d.) and its 14(R)-hydroxy metabolite 
 
Model Parameter Unit 
Point 
estimate 
95% CI 
Pharmacokinetic 
parameters 
Weibull absorption rate constant (kw) hr
-1 0.56 0.42 – 0.69 
Weibull shape parameter (λ)  2.23 1.67 – 2.77 
Apparent volume of distribution of clarithromycin (Vp) L 172 145 – 198 
Apparent total clearance of clarithromycin (CLp) L/hr 60 40 – 80 
Non-inhibited fraction of clarithromycin clearance (FCLp)  0.10 0.02 – 0.17 
Transfer ate constant into and from inhibition compartment (ki) hr
-1 2.01 0.09 – 3.93 
Concentration in the inhibition compartment yielding 50% inhibition of 
maximum clearance (IC50) 
µg/mL 0.77 0.23 – 1.28 
Apparent total clearance of 14-OH-clarithromycin (CLmet) L/hr 50.2 42.3 – 58.1 
Apparent volume of distribution of 14-OH-clarithromycin (Vmet ) L 34 12 – 56 
Between subject 
variability* 
 
Between subject variability in  kw  45.3* 7.93%
& 
Between subject variability in Vp  25.3* 2.83%
& 
Between subject variability in CLp  17.4* 1.15%
& 
Between subject variability in CLmet  27.9* 2.11%
& 
Residual 
variability 
Additive  error of clarithromycin µg/mL 0.12 2.40%& 
Additive  error of 14-OH-clarithromycin µg/mL 0.01 0.18%& 
* Coefficient of variation (%); 
&
: These percentages are relative standard errors of the estimated variance. 
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Table 6: Simulation of main PK/PD parameters of clarithromycin and 14-(R) hydroxyclarithomycin after multiple ascending doses using the 
population model estimates. 
Values were calculated on a basis of twice daily oral dosing and represent median and 90% nonparametric prediction intervals. fAUCinitial 0-24 h and 
fAUCss, 24h are the areas under the free concentration-time curves over 24h on the first day and in steady-state. The fAUC was calculated by correcting the 
total AUC for the free fraction (f) which is 0.3 assuming non-significant change in protein binding (Peters and Clissold 1992; Traunmuller et al. 2007).  
na: not applicable.  
a
 assuming that a (fAUC ss, 24 h plasma) /MIC ratio target of at least 35 h is desirable in humans for pathogens eradication (Tessier et al. 2002)
 
Dose (mg) 
fAUCinitial 0-24 h 
90% PI 
(µg •h /mL) 
fAUC ss, 24 h 
90% PI 
(µg •h /mL) 
Probability of target attainment (%) on steady state at different MIC 
values a 
0.03 
mg/L 
0.06 
mg/L 
0.125 
mg/L 
0.25 
mg/L 
0.5 
mg/L 
1 
mg/L 
2 
mg/L 
4 
mg/L 
cl
ar
it
h
ro
m
yc
in
 
250 4.64 
(1.06 – 9.20) 
5.1 
(1.19 – 10.18) 
100 99 56 3 0 0 0 0 
500 11.11 
(5.10 – 20.0) 
15.10 
(6.9 – 31.9) 
100 100 100 91 43 3 0 0 
750 19.74 
(10.9 – 34.7) 
33.4 
(17.4 – 62) 
100 100 100 100 92 49 2 0 
1000 28.71 
(18.2 – 51.2) 
54.3 
(30.4 – 95.0) 
100 100 100 100 100 83 24 0 
14
-O
H
-
cl
ar
it
h
ro
m
yc
in
 
250 2.83 
(1.16 – 5.07) 
3.17 
(1.29 – 5.57) 
na 
500 5.0 
(2.45 – 8.39) 
6.29 
(3.29 – 10.25) 
na 
750 6.81 
(3.75 – 11.14) 
9.42 
(5.34 – 15.10) 
na 
1000 8.29 
(4.46 – 13.63) 
12.48 
(7.24 – 19.19) 
na 
75 
 
3.3 Dextromethorphan 
A total number of 1346 concentrations (537 plasma samples, 136 urine samples of 
dextromethorphan and a similar number of observations for dextrorphan) from 36 healthy 
Caucasian men obtained after oral administration of a 30 mg dextromethorphan-HBr dose 
were analysed in this study. The CYP2D6 genetic characteristics of these volunteers are given 
in Table 7.  
Table 7: CYP2D6 Genotypes of 36 individuals participated in dextromethorphan study. 
CYP2D6 variants Study A Study B Study C Total 
O
b
se
rv
e
d
 a
lle
le
s 
*1 13 11 5 29 
*1x2 1 1 0 2 
*2 5 0 11 16 
*2x2 1 1 0 2 
*3 0 1 0 1 
*4 9 2 3 14 
*4x2 0 0 1 1 
*6 0 0 0 0 
*41 1 4 2 7 
*41x2 0 0 0 0 
O
b
se
rv
ed
 g
en
o
ty
p
es
 
*1/*1 2 3 1 6 
*1/*2 2 0 2 4 
*1/*4 6 1 0 7 
*1/*41 1 3 1 5 
*4/*4 1 0 0 1 
*2/*4 1 0 3 4 
*2/*41 0 0 1 1 
*6/*41 0 0 0 0 
*4/*41 0 1 0 1 
*1x2/*2 1 0 0 1 
*1/*1x2 0 1 0 1 
*2/*2x2 1 0 0 1 
*2x2/*3 0 1 0 1 
*2/*2 0 0 2 2 
*2/*4x2 0 0 1 1 
 
In general, there were large interindividual differences in the time-concentration profiles of 
the whole data, with the highest variability in case of dextromethorphan. Dextromethorphan 
initial plasma concentrations decreased rapidly in many but not all individuals (within the 
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first 5 hours after dosing) indicating the known variability in drug clearance. Dextrorphan 
plasma concentrations appeared in many individuals earlier than the parent supporting the 
importance of first-pass metabolism (Figure 23).  
 
 
 
Figure 23: Actual dextromethorphan and dextrorphan observations in plasma and urine. 
Uper panel: plasma concentrations over time of dextromethorphan (filled circles) and dextrorphan 
(unfilled circles). Lower panel: cumulative amount in urine over time of dextromethorphan (filled 
circles) and dextrorphan (unfilled circles) 
 
 
The values obtained from non-compartmental analysis for the area under the concentration-
time curve (AUC), maximal observed plasma concentrations (Cmax), the corresponding times 
(tmax), and the elimination rate constant for dextromethorphan and dextrorphan are 
summarized in plasma are given in Table 8. 
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Table 8: Non-compartmental pharmacokinetics of dextromethoephan and dextrorphan in 
plasma  
Parameters Study arm 
Study A Study B Study C 
D
ex
tr
o
m
et
h
o
rp
h
an
 
tlag (hr) 0.41  ± 0.33 
( 0.0 – 1.33) 
0.41 ± 0.28 
( 0.0 – 1.0) 
0.41 ± 0.11 
( 0 – 0.5) 
tmax 
(hr) 
1.95 ± 0.94 
(0.50 - 3.25) 
1.97  ± 0.68 
(1.33 – 3.25) 
2.67 ± 0.88 
(0.75- 3.95) 
Cmax 
(µg/L) 
2.36 ± 5.52 
( 0.18- 22.2) 
1.92 ± 4.35 
(0.16 – 14.24) 
2.69 ± 2.75 
(0.22-8.33) 
AUCt 
(µg/L/hr) 
30  ±  95 
(0.12 – 373) 
21 ± 56 
(0.26 -181) 
15.44 ± 17.59 
(0.47- 55.78) 
AUCinf  
(µg/L/hr) 
94.7  ±  342 
(0.35- 1330) 
30.88 ± 83.53 
(0.72- 268.36) 
23.50 ± 25.95 
(1.26 – 85.07) 
Vz/F 
(L) 
60117 ± 52521 
(1338-190070) 
76463 ± 53823 
(2180-177310) 
23887 ± 25782 
(3425-93001) 
CL/F 
(L/hr) 
13251 ± 21297 
(23 - 84795) 
12555 ± 12220 
(112-41619) 
4306 ± 6965 
(353- 23813) 
kel  
(1/hr) 
0.159  ± 0.103 
(0.017-0.446) 
0.146  ± 0.082 
(0.051-0.309) 
0.143 ± 0.045 
(0.102-0.256) 
t1/2   
(hr) 
7.84 ± 9.73 
( 1.55 - 41.11) 
6.45 ± 3.84 
(2.25 – 13.52) 
5.16 ± 1.20 
( 2.71- 6.78) 
D
ex
tr
o
rp
h
an
 
tlag  
(h) 
0.19 ± 0.18 
( 0.0 - 0.5) 
0.33 ± 0.11 
(0.17 -  0.50) 
0.29 ± 0.11 
(0.17 -0.50) 
tmax 
(hr) 
1.58  ± 0.88 
( 0.75 – 3.25) 
1.47 ± 0.69 
(0.75 -3.25) 
1.73  ± 0.85 
( 0.5 -3.25) 
Cmax 
(µg/L) 
5.33 ± 2.45 
( 0.42- 9.8) 
4.70 ± 1.99 
(1.46 – 8.86) 
6.37  ± 2.92 
(2.65 - 11.44) 
AUCt 
(µg/L/hr) 
22.4  ± 6.56 
(5.18 - 34.4) 
16.58  ± 6.45 
(8.60 – 31.03) 
22.94 ± 12.67 
( 5.06- 48.9) 
AUCinf  
(µg/L/hr) 
23.86  ± 6.56 
(7.65- 35.54) 
17.58  ± 6.68 
( 9.25- 32) 
25.34 ± 13.95 
( 5.68- 54.24) 
Vz/F 
(L) 
12087 ± 16032 
( 4164- 68793) 
10221 ± 5017 
(4443 - 17989) 
7777 ± 5143 
( 2263-21002) 
CL/F 
(L/hr) 
1422 ± 738 
(844- 3922) 
1929  ± 705 
( 938 - 3244) 
1690 ± 1320 
( 553- 5286) 
kel  
(1/hr) 
0.163   ± 0.063 
(  0.057-  0.28) 
0.206  ± 0.055 
( 0.078-0.272) 
0.214  ± 0.032 
(0.165-0.254) 
t1/2   
(hr) 
5.02 ± 2.48 
( 2.47- 12.16) 
5.60  ± 3.25 
( 3.14-14.29) 
3.31  ± 0.53 
(2.73 –  4.21) 
Dextromethorphan was administered as a single oral dose of 30 mg. The last plasma samples were 
obtained at 24 hr in study A, and B, and 12 hr in study C (see method section). tmax is the time of 
maximum concentration (Cmax); t1/2is the elimination half life; kel is the elimination rate constant, AUCt 
and AUCinf are the area under the plasma concentration-time curve up to last observation and infinity; 
Vz/F is the apparent volume of distribution, and CL/F is the apparent total clearance. 
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Modelling all data with the basic structure 4-compartment model (see Methods section) was 
not sufficient to describe the data, with misspecifications especially for parent 
concentrations in plasma. Addition of a peripheral compartment for dextromethorphan was 
associated with a significant drop in the objective function value (ΔOFV = -114). Based on 
individual and population predictions, this model was still unable to account for the early 
appearance of dextrorphan in plasma. Therefore, other models (Piotrovskij 1997; 
Moghadamnia et al. 2003; Levi et al. 2007) that take the first pass metabolism into account 
were tested. These models were stepwise simplified or extended for modelling the available 
data. A hypothetical metabolism compartment was added, which was assumed to be in 
rapid equilibrium with the central compartment of the parent drug, with all metabolic steps 
taking place in this compartment. After administration of the drug, it was assumed that the 
drug goes from the absorption site to the metabolism compartment before reaching the 
plasma. The model specifications are given in appendix A. This model was associated with a 
profound drop in the objective function value (ΔOFV = -324). Inclusion of a lag-time 
parameter led also to further significant drop in the objective function (ΔOFV = - 45). 
Disposition kinetics revealed that dextromethorphan is widely distributed and rapidly 
metabolized to dextrorphan. As expected, CYP2D6 genotype had a major impact on the 
metabolic clearance (ΔOFV = - 532). About 55% of the interindividual variability (CV %) in 
dextromethorphan metabolic clearance, CL23, was explained by addition of 2D6 genotypes. 
Inclusion of urine pH values as a covariate on renal clearance of dextromethorphan led to 
significant drop in objective function value (Δ OFV= -105). The best form of this relationship 
was that included in the final model and is described by the following empirical equation: 
s
r
pH
TVCLCL








7.5
 
where, CLr is the individual value of renal clearance, TVCL is the population value of renal 
clearance, the value 5.7 represent a published mean of urine pH in humans (Florence, A T 
and Attwood, D 2006), pH is the measured individual urine pH at each collection period, and 
θs is the shape parameter which explains the change in renal clearance in terms of change in 
urine pH on renal. Using the non-ionized fraction of dextromethorphan calculated according 
the Henderson-Hasselbalch equation as a covariate was not superior to this equation. 
Including an effect of urine pH on renal clearance of dextrorphan did neither improve model 
fitting nor led to a decrease in the OFV value. 
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The model identified age as a recognizable covariate contributing to interindividual 
variability in apparent volume of distribution of dextrorphan (Δ OFV = -21.9) and the 
clearance of dextrorphan to other species, CL30, (Δ OFV = -5.8). This covariate was modelled 
according to the relationship: 
θPV = θPV ∙ EXP (θAGE  ∙ (AGE – 27) 
θPV is the population value of the model parameter, θTV is the typical value in an individual 
with age of 27 years (the median age in this study). θAGE is the fractional change in θPV per 
year different from 27 years of age. None of other apparent volumes of distribution, 
clearance, or intercompartmental clearance parameters has been found to be influenced by 
age in this study. Neither subject’s body weight nor body height was found as significant 
covariates on model disposition parameters. 
Plasma data were best fitted if a combination of an additive and proportional error terms 
were used, while urine data were best fitted with proportional error terms. The blueprint of 
the final model is shown in Figure 24 and its specifications are given in Figure 25. The 
descriptive equations used are explained in Figure 26.  
The final pharmacokinetic parameter estimates with the corresponding 95% confidence 
intervals are shown in Table 9. The apparent metabolic clearance (CL23) estimate ranged 
from 10 to 10030 L/h in this population. In view of a hepatic blood flow of approximately 
1.35 L/min in healthy young volunteers (Yzet et al. 2008) it implies largely extrahepatic 
metabolism. This is in accordance with the large apparent volume of distribution. The 
fraction of this clearance attributable to the presence of the *1 allele was on an average of 
2.5-fold greater than that mediated by allele*2, whereas the *41 allele showed the lowest 
activity: the point estimates per each *1 allele is 5010 L/h versus 2020 L/h per the *2 allele 
and 85 L/h per the *41 allele. 
Diagnostic plots of the final model are given in Figure 27 for plasma data and in Figure 28 for 
urine data showing the model adequacy. The simulated 5th, 50th and 95th percentiles from 
the simulated data, based on the final model estimates, are shown in Figure 29. Examples of 
individual fitting are shown in Figure 30. Simulated time courses of plasma concentrations 
and cumulative amounts excreted in urine for different genotypes with homozygosity for 
individual alleles are given in Figure 31. The expected values for the metabolic ratio of these 
genotype for standard CYP2D6 phenotypic metrics (i.,e., at 3h in plasma and 0-8h in urine) 
are given in Table 10. 
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Figure 24: Blueprint of the final population pharmacokinetic model of dextrometorphan. 
 
A semi-mechanistic population model was uses to describe dextromethorphan (DEX) and dextrorphan 
(DOR) in plasma and urine after administration of single oral doses of 30 mg dextromethorphan 
hydrobromide. The absorption phase is described with a rate constant (ka) and lag time (tlag). Cz  is the 
concentration of dextromethorphan in the hypothetical metabolizing enzyme compartment 
(METENZ), which is in rapid equilibration with that in plasma. Q1 is the intercompartmental clearance 
between central compartment of DEX and METENZ. Cp and Cu are plasma and urine concentration of 
DEX or DOR in the corresponding compartment. CL23 is the apparent systemic metabolic clearance of 
DEX to DOR, which is the sum of CYP2D6-mediated clearance (CLCYP2D6) and non-CYP2D6 
mediated clearance (CLb). Q2 is the intercompartmental clearance between central and peripheral 
compartments of dextromethorphan, CL24 is the renal clearance of DEX under the influence of urine 
pH (UpH), CL35 represents DOR renal clearance, and CL30 is the clearance of DOR to other species. 
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Figure 25: Relevant NONMEM code of the final dextromethorphan model  
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Figure 26: Dextromethorphan model differential equations 
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Figure 27: Goodness-of-fit plots for plasma concentrations of dextromethorphan (left) and 
dextrorphan (right) 
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Figure 28: Goodness-of-fit plots for amounts excreted in urine of dextromethorphan (left) and 
dextrorphan (right) 
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Figure 29: Visual predictive check plots of dextromethorphan population model. 
Actual data (filled black circles=dextromethorphan data, unfilled circles= dextrorphan) are almost 
equally dispersed on the both side of simulated median (50
th
 percentile). Plasma observations are 
shown on the upper panel. 
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Figure 30: Examples of individual fitting of dextromethorphan (left) and dextrorphan (right) 
concentrations in plasma (circles = observations, line=individual predictions) 
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Figure 31: Simulated typical time courses in plasma and urine for individuals with different 
CYP2D6 genotypes 
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Table 9a: Population pharmacokinetic estimates of dextromethorphan and dextrorphan 
Model parameter§ Point 
estimate 
Standard 
error 
B
as
ic
 P
h
ar
m
ac
o
ki
n
et
ic
 P
ar
am
et
er
s 
Absorption rate constant , ka 
  0.25 0.23 – 0.27 
Lag time  0.31 0.30 – 0.32 
Apparent volume of distribution of dextromethorphan in 
central compartment   Vc,,dex 
648 493 - 803 
Intercompartmental clearance Q1 560 295 - 825 
Apparent volume of distribution of dextromethorphan in 
peripheral compartment  Vp, dex 
1560 1092 - 2028 
Intercompartmental clearance Q2 173 129 - 217 
Apparent renal clearance of dextromethorphan CL24 6.52 4.84 – 8.20 
Urine pH effect on dextromethorphan renal clearance in a 
man with a standard pH value of 5.7 
3.93 2.74 – 5.12 
Metabolic 
clearance 
CL23 
BCL23  10.1 6.38 – 13.82 
Allele *1 5010 3579 – 6441 
Allele *2 2020 624 - 3416 
Allele *41  85.0 63.8 – 106.2 
Apparent volume of distribution of dextrorphan Vm, dor 419 237 - 601 
Age effect  on  Vm, dor (% change/ year)** 0.042 0.016 – 0.068 
Apparent renal clearance of  dextrorphan CL35 45.5 34.1 – 56.9 
Apparent clearance of dextrorphan to other species  CL30 1260 1061 - 1460 
Age effect  on  CL30 (% change/ year)** 0.029 0.003 – 0.055 
B
et
w
ee
n
 s
u
b
je
ct
s 
va
ri
ab
ili
ty
 (
B
SV
) 
BSV_ka (%CV) 20.1 1.3* 
BSV_CL24 (%CV) 69.5 12.5* 
BSV_ CL23 (%CV) 73.8 13.6* 
BSV_CL35 (%CV) 73.8 10.6* 
BSV_CL30 (%CV) 44.3 5.18* 
R
es
id
u
al
 v
ar
ia
b
ili
ty
  
P
la
sm
a 
DEX 
Proportional error (CV %) 30.6 1.61* 
Additive error (ng/mL) 0.004 0.122* 
DOR 
Proportional error (CV %) 32.6 1.06* 
Additive error (ng/mL) 0.006 0.18* 
U
ri
n
e 
DEX Proportional error (CV %) 56.2 3.82* 
DOR Proportional error (CV %) 44.8 2.95* 
§
see Figure 24 for individual parameters; *= percentage of relative standard error 
** centered around 27 years 
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Table 10:  Expected [dextrorphan/ dextromethorphan] metabolic ratios in plasma and urine for 
different genotype* 
Genotype *1/*1 *2/*2 *41/*41 *4/*4 
Plasma metabolic ratio (3h) 8.6 3.61 0.20 0.011 
Urinary metabolic ratio (0-8 h) 68.2 26.6 1.26 0.07 
*27 years old male having urine pH of 5.7 
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3.4 Phenprocoumon 
Relative frequency of CYP2C9 alleles was CYP2C9*1, 79.3 %; CYP2C9*2, 13.5 %; and 
CYP2C9*3, 7.2 %). Details of CYP2C9 and VKORC1 alleles are presented below in Table 11. 
The weekly phenprocoumon dose ranged from 3.75 to 37.5 mg. There were large 
interindividual differences in plasma concentrations especially for the parent substance. 
Mean trough plasma concentration ± SD (range) of phenprocoumon, 4`-OH phenprocoumon and 
7-OH phenprocoumon were 2744 ± 1057 (256 – 6510), 56.1 ± 27.3 (11.5 – 137), and 63.8 ± 31.9 (6.8 
– 163) ng/mL, respectively. Measured INR values ranged from 1.10 to 5 (mean±SD: 2.54±0.57). 
Table 11:  Observed CYP2C9 and VKORC1 genotypes of 278 patients participated in 
phenprocoumon study. 
Characteristics Value 
C
Y
P
2
C
9
  
ge
n
o
ty
p
e
s 
*1/*1 172 
*1/*2 61 
*1/*3 36 
*2/*2 5 
*2/*3 4 
*3/*3 0 
V
K
O
R
C
1 
 g
en
o
ty
p
es
 
 
1173C > T 
CC 97 
CT 130 
TT 51 
 
36G > A 
GG 271 
GA 7 
AA 0 
 
85G > A 
GG 277 
GA 1 
AA 0 
 
106G > T 
(Asp36Tyr) 
GG 276 
GT 2 
TT 0 
 
129C > T 
CC 275 
CT 3 
TT 0 
 
358C > T 
CC 275 
CT 3 
TT 0 
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Categorization of doses and INR measurements for the different combination of CYP2C9 and 
VKORC1 polymorphisms in this population are given in Table 12. 
 
Table 12:  Empirically administered phenprocoumon dose and measured INR values of 
participants for each CYP2C9 and VKORC1 polymorphisms group. 
 CYP2C9 
*1/*1 
CYP2C9 
*1/*2 
CYP2C9 
*1/*3 
CYP2C9 
*2/*2 
CYP2C9 
*2/*3 
V
K
O
R
C
1
 C
C
 Dose 
(mg /week) 
17.89  ±  5.47 
(7.5 – 28.5) 
14.83  ± 6.97 
(6 – 37.5) 
14.08  ± 3.80 
(7.5 – 21) 
15 NA 
INR 2.48  ±  0.51 
(1.4 – 3.71) 
2.23  ±  0.50 
(1.1 – 3.0) 
2.77  ±  0.55 
(2.0 – 3.62) 
1.7 NA 
n 61 22 13 1 NA 
V
K
O
R
C
1
 C
T
 Dose 
(mg /week) 
14.50  ±  5.42 
(4.5 - 36) 
12.88  ± 4.23 
(5.25 – 22.5) 
10.78  ± 2.97 
(5.25 – 19.5) 
9.58  ±  0.80 
(9 – 10.5) 
9.0  ± 5.41 
(4.5 – 15) 
INR 2.60  ±  0.63 
(1.58 – 5.0) 
2.63  ±  0.66 
(1.2 – 3.8) 
2.59  ±  0.50 
(1.47 – 3.8) 
2.90  ±  0.26 
(2.6 – 3.1) 
2.51  ± 0.41 
(2.07 – 2.89) 
n 78 26 20 3 3 
V
K
O
R
C
1
 T
T
 Dose 
(mg /week) 
9.47  ±  5.41 
(3.75 – 15.0) 
6.84  ±  2.89 
(3.75 – 10.5) 
8.00  ±  2.27 
(6.0 – 9.0) 
6.00 5.25 
INR 2.55  ±  0.41 
(1.5 – 3.6) 
2.62  ±  0.56 
(1.7 – 3.48) 
2.66  ±  0.52 
(2.42 – 2.9) 
NA 1.50 
n 33 13 3 1 1 
Data given as mean ± SD (range); n= number of patients in each group 
 
 
Empirical dose requirements: 
There was no obvious effect of CYP2C9 and/or VKORC1 genotype on the INR reached, with 
mean values for the individual groups randomly distributed in the 2.23-2.90 range (Table 
12). In contrast, the effect of CYP2C9 polymorphism in this population is reflected by a 
higher dose requirement for CYP *1/*1 carriers compared to carriers of mutant alleles. The 
difference is approximately 1.25-fold relative to heterozygote carriers of one mutant allele 
and 1.5-fold compare to *2/*2 individuals. VKORC1 CC carriers required a 2-fold higher dose 
than TT carriers, with heterozygous individuals in between.  
 
PK model: 
All plasma concentrations of the parent and its metabolites were evaluated simultaneously. 
A three compartment model was found appropriate to describe the data of the parent at its 
4´- and 7-hydroxy metabolites.  
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The total apparent clearance of phenprocoumon (CLt) was defined as the sum of metabolic 
clearance mediated by CYP2C9 enzyme (CLCYP2C9) and other pathways (CLN2C9) as follows: 
                             
CLt = CLCYP2C9 + CLN2C9 
where CLCYP2C9 was coded as:  
CLCYP2C9 = n*1 · CL*1+ n*2 · CL*2 + n*3 · CL*3 
 
The CL*1, CL*2 and CL*3  stand for the activity of each *1, *2 and 3 individual allele, and n*1, 
n*2,·and n*3 for the number of these alleles, respectively. 
The formation clearance of PPC to 4-hydroxy (CL4'-OH) and 7-hydroxy (CL7-OH) metabolites 
were assumed to be mediated by CYP2C9 as 
 
CL4'-OH = f4'-OH · CLCYP2C9 
CL7-OH  = f7-OH · CLCYP2C9 
 
where f4'-OH and f7-OH are the fraction of total CLCYP2C9 resulting in 4'-OH and 7-OH metabolites 
formation. To maintain the mass balance, the clearance of phenprocoumon to non-*4’- and 
7-]-hydroxymetabolites, CLother, was modelled according to the following equations: 
 
CLother = CLt – (CL4'-OH + CL7-OH) 
 
Identified covariates contributing significantly to the interindividual variability and model 
fitting were CYP2C9 variants, age, and body weight. Inclusion of patients alleles in the model 
led to marked drop in the objective function value compared with a model without CYP2C9 
information (∆OFV= - 38). An age dependent decrease of clearance modeled via an apparent 
proportional decrease function was associated with significant drop in the OFV (∆OFV= - 35). 
Centering the age model to a 50 years old patient or to the data median (70 years old) did 
not improve the model (∆OFV= - 0.3). Body mass index did not result in model improvement 
(∆OFV= - 0), while inclusion of body weight led to additional drop in the objective function 
value (∆OFV= - 28). Finally, inclusion of sex as a covariate led to significant drop in objective 
function (∆OFV= -5), but the 95% confidence interval included unity. Therefore, the impact 
of this covariate was excluded in the final model.  
Inclusion of individual habits, alcohol, coffee, tea, and cola drinking did not lead to a 
significant drop in the objective function. Accordingly, the final PK model included individual 
RESULTS 
 
93 
 
CYP2C9 alleles, age, and total body weight as important covariates on the total clearance of 
phenprocoumon. They were best described according to the following relationship: 
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An interindividual variability term was quantified on the total apparent clearance of 
phenprocoumon. A blueprint of the assumed PK population model is given in Figure 32. The 
control stream of the final PK model is given in Figure 33. 
The model identified notable differences in the metabolic activity between CYP2C9 alleles. 
The estimated metabolic activity value were about 12.3, 6.5, and 2.9 mL/h for *1, *2, and *3 
alleles (per allele), respectively. The resulting pronounced differences for the respective 
genotypes however were dampened by a clearance fraction not mediated by CYP2C9 of 15.1 
mL/h. A summary of population pharmacokinetic parameters estimates of the final model is 
shown in Table 13. The Goodness-of-fit plots of the pharmacokinetic model are given in 
Figure 34.  
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Figure 32: Blueprint of the final population PK-PD model of phenprocoumon (PPC) and its 4'- 
and 7-hydroxy metabolites.  
 
Drug input was modelled as a constant infusion of administered dose per week, CLT is the total 
clearance of PPC, CLN2C9 is the non-CYP2C9 mediated clearance of PPC, CLCYP2C9 is the CYP2C9-
mediated clearance of PPC, f4'-OH and f7-OH are the respective fractions of CLCYP2C9 resulting in 4'-OH 
and 7-OH metabolites formation, CLCYP2C9,other is the CYP2C9-mediated clearance of PPC not 
resulting in formation of 4´-OH or 7-OH metabolites, INR is the international normalized ratio, SCC, 
SCT, and  STT  control the rate increase in PPC response according to vitamin K epoxy reductase 
complex 1 (VKORC1) variants.  
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The NONMEM code used for phenprocoumon pharmacokinetic model 
 
 
 
 
 
 
 
Figure 33: Relevant NONMEM code of the final phenprocoumon PK-model 
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Figure 34: Goodness-of-fit plots for the final pharmacokinetic model of phenprocoumon 
Phenprocoumon (filled circles), 4'-hydroxy phenprocoumon (open circles) and 7-hydroxy 
phenprocoumon (triangles) 
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Table 13: Population pharmacodynamic parameter estimates of phenprocoumon (PPC) 
Parameters 
Point 
estimates 
95% CI 
Clearance of PPC (CLCYP2C9) 
per individual CYP2C9 allele 
CYP 2C9 *1 (mL/h) 12.3 7.62 – 16.98 
CYP 2C9 *2 (mL/h) 6.53 3.20 – 9.86 
CYP 2C9 *3 (mL/h) 2.85 0.10 – 5.61 
CLNon-2C9; clearance of PPC by non-CYP2C9 pathway (mL/h) 15.1 7.24 – 22.96 
Between subject variability in the apparent PPC total CL (% CV) 30 9.7* 
f4'-OH; fraction of CLCYP2C9 responsible for 4'-OH-PPC formation 0.15 0.09 – 0.21 
Apparent clearance of 4´-OH-PPC  (mL/h) 144 114 - 174 
f7-OH; proportion of total CYP2C9 mediated clearance 
responsible for 7-OH-PPC formation 
0.49 0.45 – 0.53 
Exponential decline rate of total PPC clearance after 50 years 
(ml/hr/year) 
5.48 3.59 – 7.37 
Apparent clearance of 7-OH-PPC  (mL/h) 543 436 - 650 
Additive residual error for PPC concentrations (µg/mL) 0.1 fixed n.a 
Additive residual error for 4'-OH-PPC concentrations (ng/mL) 8 fixed n.a 
Additive residual error for 7-OH-PPC concentrations (ng/mL) 8 fixed n.a 
n.a.= not applicable. 
*= percentage of standard error  
 
 
 
 
 
PD model:  
The following linear model was assumed to predict INR:   
INR=E0+CPPC · SF 
where E0 is the basal level corresponding to the dose=0. This parameter was assumed to be one in 
these evaluations, CPPC is the predicted concentration of phenprocoumon at steady state, and SF 
(sensitivity factor) is a parameter governing the patient´s sensitivity to phenprocoumon. The 
variability in VKORC1 gene was assumed to be the major determinant factor of pharmacodynamics 
variability of phenprocoumon (Reitsma et al. 2005; Schalekamp et al. 2007; Stehle et al. 2008). The 
VKORC1 polymorphisms were coded as  
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The contribution of VKORC1 genotypes was identified as an important covariate. Subdividing 
the population into three groups CC, CT and TT was associated with a profound drop in the 
objective function value (∆OFV= - 106). Inclusion of other covariates did not improve the 
model fitting and none of them led to a significant decrease in the objective function. 
Accordingly, the final PD model includes only VKORC1 variants as covariates (Figure 32). The 
control stream of the final PD model is given in Figure 35. The goodness-of-fit plots of the 
pharmacodynamic model are given in Figure 36.  
 
 
 
 
 
 
Figure 35: Relevant NONMEM code of the final phenprocoumon PD-model 
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Figure 36: Goodness-of-fit plots for the final pharmacodynamic model of phenprocoumon 
Population predictions of INR represented as filled circles (base model) and open circles (final model) 
without and with VKORC1 polymorphisms, respectively. 
 
 
Summary of population pharmacodynamic parameters estimates from the final model are 
shown in Table 14. From this table, the highest values of the sensitivity factor (SF) was 
observed for the VKORC1 TT variant, while the wild type CC shows lower sensitivity. Based 
on these estimates, the trough phenprocoumon plasma concentrations required to reach a 
target INR value of 2.5 for individuals with CC, CT and TT variants of VKORC1 is 3.57, 2.5, and 
1.82 µg/mL, respectively. 
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Table 14: Population pharmacodynamic parameter estimates of phenprocoumon 
Parameters Point estimates 95%CI 
Basal INR value (E0) 1 Fixed n.a. 
SF  VKORC1 CC genotype 0.42 0.38 – 0.46 
SF  for VKORC1 CT genotype 0.60 0.55 – 0.64 
SF  for VKORC1 TT genotype 0.83 0.74 – 0.91 
Interindividual variability in SF (CV %) 39.6 12.2* 
Residual (additive) error for INR 0.033 Fixed n.a. 
E0 is the basal INR level corresponding to dose=0, SF is a parameter governing the patient´s sensitivity 
to phenprocoumon, n.a.=not applicable. 
*= percentage of standard error  
 
 
 
Simulation of phanprocoumon PK/PD profiles: 
Simulation of Based of steady state phenprocoumon plasma concentration profiles displays 
different scenarios according to CYP2C9 genotypes (Figure 37).  
 
Figure 37: Simulated mean phenprocoumon plasma concentrations for the different CYP2C9 
genotypes based on final model parameters. 
 (dose=2 mg/day, age=45 years, total body weight =70 kg). A volume of distribution of 12 L and 
absorption rate constant of 2 h
-1
 were assumed (Kitteringham et al. 1984; Kitteringham et al. 1985; 
Haustein and Huller 1994; Masche et al. 1999).  
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The simulation results for the effect of VKORC1 polymorphisms on determining the INR level, 
for the wild-type 2C9 *1/*1 genotype, is given in Figure 38. 
 
Figure 38: Simulated INR levels for different VKORC1 variants in individuals carrying 
CYP2C9 *1/*1 genotype.  
Simulated plasma concentration for CYP2C9*1/*1 carriers given in Figure 38 were used to drive INR 
prediction in PD-model.  
 
 
Maintenance dose calculations: 
Based on final PK/PD parameter estimates, the maintenance daily dose for phenprocoumon 
required to achieve a steady state INR of 2.5 in 18 different genetic combinations of CYP2C9 
and VKORC1 polymorphism are given in Table 15.  
 
Table 15: Predicted daily dose (mg) to achieve a steady state INR value of 2.5 in typical 
individuals having different combination of CYP2C9 and VKORC1 genotypes* 
Genotypes 
CYP2C9 
*1/*1 *1/*2 *1/*3 *2/*2 *2/*3 *3/*3 
V
K
O
R
C
1
 CC 3.61 3.08 2.75 2.56 2.22 1.89 
CT 2.52 2.16 1.92 1.79 1.56 1.32 
TT 1.84 1.57 1.40 1.30 1.13 0.96 
*assuming a typical individual of 45 years old and 70 kg body weight  
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General algorithm to calculate the maintenance daily doses of phenprocoumon: 
The daily maintenance doses (Table 15) were calculated according to the following 
equations: 
 
tav CLCFDose   
Where Dose is the required dose, F is the bioavailable fraction of drug (this evaluation 
assumed 100% bioavailability i.e., F=1), avC is the average plasma concentration at steady 
state required to achieve a presumed target INR, and tCL is the total drug clearance. Based 
on VKORC1 variant avC  can be determined according to the following equation 
VKORC1geneTTfor
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is the basic INR level in the absence of drug ( 0E  was assumed to be one in this 
evaluations). The total clearance of phenprocoumon (CLt) can be determined by the derived 
total clearance equation 
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Where n*1, n*2, and n*3 are the number of *1,*2,*3 alleles in individual CYP2C9 genotypes.  
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4.1 Fluorescein 
An ocular population model has been presented that adequately describes fluorescein 
pharmacokinetics in the anterior eye segment and estimates ocular and resulting systemic 
bioavailability of fluorescein from a lyophilisate relative to an eye-drop formulation in 
humans. These results confirm the original results (Dinslage et al. 2002; Lux et al. 2003; 
Steinfeld et al. 2004) of rapid release of the drug from lyophilisate and the higher 
bioavailability achieved from this formulation and provides a quantitative estimate for the 
difference. 
Fluorescein sodium is a water-soluble ophthalmologic diagnostic substance with a negligible 
binding affinity to any vital tissue, which accounts for its low toxicity. It is freely and widely 
distributed into ocular structures by diffusion; however, active transport is needed to reach 
the retina (Maurice 1967). After topical instillation of fluorescein as a solution, like any other 
aqueous preparation, the drug is rapidly washed out by tear secretion depending on the 
degree of lacrimation. The massive pre-corneal loss of fluorescein significantly limits its 
ocular bioavailability and presents unique challenges for achieving high concentration in the 
internal structures of the eye (Maurice 1967; Adler et al. 1971; Mishima 1981; Linden and 
Alm 1997). 
 
Different efforts have been made to enhance fluorescein bioavailability from conventional 
eye drops, all of which are based on prolonging the contact time on the ocular surface by 
way of increasing vehicle viscosity or topical instillation of large volume. Increasing vehicle 
viscosity in conventional eye drops may enhance fluorescein retention and decrease 
fluorescein loss via lacrimation (Adler et al. 1971; Ludwig et al. 1992; Linden and Alm 1997), 
but increasing viscosity is clinically limited by the corresponding increase in irritation and 
blurred vision that occur with some gel forming agents resulting in lacrimation and a higher 
blink frequency (Ludwig et al. 1992). Actually, the observed increase in the pre-corneal tear 
film retention was found to be mainly due to an increase in the tear reservoir volume of the 
delivery vehicle and not to be viscosity dependent (Benedetto et al. 1975). On the other 
hand, administration of five consecutive 10-μL fluorescein drops at only 1-min intervals 
resulted only in twofold higher concentration in the cornea and anterior chamber for 8 h 
(Linden and Alm 1997). In contrast, noncompartmental results show that the lyophilisate 
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significantly increased ocular fluorescein concentrations and the ocular bioavailability at 
least fivefold without the need to increase the dose. The probable mechanism is that the 
freeze-dried lyophilisate formulation resides for a longer period in the lower conjunctival 
fornix, resulting in higher tear film saturation before being washed out by tear secretion 
(Dinslage et al. 2002; Lux et al. 2003). 
 
NONMEM evaluation shows a rapid absorption phase for the lyophilisate formulation. The 
absorption rate constant (ka) was estimated at 16.7 h
−1 (95% CI 12.3–21.1), which 
corresponds to an absorption half-life of about 2.5 min (calculated as t1/2 =ln2/ka). The 
absorption process is slower and longer than that after administration of eye drops, where 
absorption appeared to be completed at the time of the first measurement in study 1, i.e., 
after not more than 2 min. The shortness of the absorption phase from eye drops could be 
ascribed to the rapid loss of the drug from the conjunctival fornix. The prolonged absorption 
observed with the lyophilisate confirms the assumption of a longer pre-corneal/formulation 
contact time as the reason for effective absorption of fluorescein from lyophilisate (Dinslage 
et al. 2002). Furthermore, lyophilisate probably decreases its pre-corneal loss by reducing 
tear turnover because of its preservative-free properties. 
As soon as the fluorescein enters the cornea, it is rapidly distributed, mainly into the anterior 
chamber and then to other ocular tissues and the blood stream (Maurice 1967; McLaren et 
al. 1993). Alternatively, part of the absorbed fraction of the dose may be eliminated by the 
tears after which it enters the gastrointestinal tract via the nasolacrimal ducts and is 
reabsorbed into the circulation. The compartmental model indicates that the systemic 
bioavailability of fluorescein from lyophilisates via the ocular route is approximately four 
times that from eye drops. This can be attributed to the improvement in the absorption 
profile of fluorescein from lyophilisate. The advantage of compartmental analysis using 
NONMEM over noncompartmental analysis is that the noncompartmental analysis directly 
compares the ocular concentrations for both formulations, while the compartmental 
analysis also compares the systemic bioavailability of fluorescein via the ocular route from 
both formulations and is also able to jointly evaluate different data sets. In this study, the 
systemic fluorescein concentration in plasma was not measured, thus, the systemic 
bioavailability of fluorescein originating from intestinal absorption of the dose fraction lost 
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by lacrimation can not be judged, but probably this would be higher for the eye-drop 
formulation. 
 
4.2 Clarithromycin 
This study proposes a population pharmacokinetic model in which the nonlinearity in 
clarithromycin pharmacokinetic profile was quantitatively described in term of an inhibitable 
fraction of the total clearance. This was modelled by addition of an inhibition compartment 
to the model, where the change of clarithromycin clearance over time in the drug 
compartment is dependent on the concentration in the inhibition compartment. This study 
supports the idea of explaining the auto-inhibition effect of a drug on its metabolizing 
enzyme by inclusion of the inhibition compartment side by side to the drug compartment. 
This model was successively used to describe the inhibitory effect of linezolid on its own 
metabolizing enzyme and the nonlinear increase in the extent of bioavailability, which leads 
to the appearance of the side effects with time (Plock et al. 2007). The new features of the 
presented clarithromycin model were the incorporation of a Weibull function input, the 
allometric scaling approach for the covariate “body weight” on clearance and volumes of 
distributions, the ability to describe parent and metabolite plasma concentration profiles, as 
well as the auto-inhibition process of the parent elimination over time. 
A single Weibull function successfully described the absorption process of clarithromycin. 
The adequacy of the Weibull function emerges in its ability to reflect the change in the 
absorption process from linearity with time, most probably as a consequence of intestinal 
CYP inactivation. Thus, an adequate empirical description of the absorption phase greatly 
contributed to the successful modelling of the non-linear elimination.  
In the final model, distribution of clarithromycin throughout the body was assumed to follow 
linear kinetics and a one-compartment model was sufficient. This is in accordance with a 
previous study (Chu, S et al. 1993) and with data on tissue pharmacokinetics obtained by 
microdialysis showing that elimination rather than distribution processes govern the 
concentration vs. time profiles (Traunmuller et al. 2007). The observed peak concentrations 
shown in individual predictions versus observations plot for clarithromycin (see 
clarithromycin result Figure 17) were slightly higher than the fitted concentrations. This 
might have been caused by the presence of a second disposition compartment. Attempts to 
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estimate a model with two disposition compartments for clarithromycin however were 
unsuccessful. 
The active metabolite 14-(R) hydroxyclarithromycin may be formed in part in the 
enterocytes as a result of first pass metabolism. This process could not be modelled 
separately here because the metabolite was not administered separately neither were 
clarithromycin i.v. data available in this study. Thus, the final model assumption was that all 
clarithromycin molecules are converted to the metabolite. Modelling additional elimination 
pathways was not possible because neither metabolite formation fraction was known nor 
the metabolite was administrated intravenously. This assumption should not affect the 
quality of the model fits or its predictive performance. Modelling the elimination process of 
the hydroxyl metabolite with a saturable kinetic model did not improve the model fitting, 
however circumstantial evidence for nonlinearity has been reported (Ferrero et al. 1990b; 
Chu, S et al. 1993) as this metabolite undergoes further biotransformation (Ferrero et al. 
1990b; Yamamoto et al. 2004). 
For the final model, apparent volume of distribution of clarithromycin was 172 litres (95%CI 
145–198), which is in agreement with the previously reported range 126-306 litres (Chu, S et 
al. 1993; Traunmuller et al. 2007). The apparent total clearance of clarithromycin was 60 L/h 
and it could be inhibited to 10% of its original value (Table 5). This point estimate of oral 
clearance is the basic clearance value and decreases over time with the subsequent doses 
until steady state is achieved. Hence, it should not be compared directly with the previously 
reported range for apparent total clearances at steady state 19-105 L/h with similar 
regimens (Chu, S et al. 1993; Gorski et al. 1998; Traunmuller et al. 2007). This decrease in the 
clarithromycin clearance reflects the increasing inhibition of the metabolizing enzyme CYP3A 
during long-term clarithromycin intake, which is important to optimize dosage regimens of 
co-administered CYP3A substrates. However, while more complex inhibition models are 
probably required if other compounds that modify CYP3A4 activities or expression are 
present, the model may still be considered as long as no specific data for these substrates 
are available. Furthermore, an approximate 60 % decrease in CYP3A activity was observed 
for 500 mg clarithromycin b.i.d at the steady state (see clarithromycin results Figure 20, 
lower panel). Therefore, concentrations of co-administered CYP3A-substrates may be more 
than doubled which may reach clinical relevance (Fuhr 2008). For higher doses, a further 
pronounced decrease of CYP3A activity is to be expected. 
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The application of the fAUC/MIC concept for the current study assumes that the model 
adequately describes the pharmacokinetics of clarithromycin including its metabolism and 
that clarithromycin mediates the main part of the antimicrobial activity while the metabolite 
makes only a minor contribution. The appropriateness of the former assumption was 
confirmed via visual predictive checks. Given that the AUC of clarithromycin is approximately 
3-times as high as for its metabolite, the latter assumption seems reasonable (Jones et al. 
1990; Martin et al. 2001). The calculated fAUC24, plasma values at steady state after different 
doses indicated that the normal adult dose of 500 mg b.i.d is sufficient to produce effective 
antibacterial activity (fAUC/MIC >35 h (Traunmuller et al. 2007)) as long as the desired MIC 
of the pathogens is approximately 0.25 mg/L or lower (see clarithromycin results Table 6) 
with a probability for target attainment of 91% (see clarithromycin results Figure 22). The 
presented model suggests that increasing the dose two-fold from 500 mg b.i.d. to 1000 mg 
b.i.d. would increase steady state exposure of clarithromycin by almost 4-fold, suggesting 
that infections with pathogens with MIC values of up to 1 mg/L could be treated successfully. 
However, further clinical studies are required to support this conclusion. 
Because of both a rapid elimination and a rapid exchange with tissues including the 
inhibition compartment defined here, in subjects without hepatic and/or renal failure no 
further increase of exposure upon chronic administration of the 500 mg standard dose is 
expected after the 2nd day of treatment (see clarithromycin results Figure 21). Accordingly, 
both therapeutic action and inhibitory effects on co-administered drugs should have reached 
its maximum on the 2nd day. This provides some re-assurance that no late augmentation of 
any drug interactions would occur, although depending on the co-administered drug it may 
take longer than 2 days to subsequently reach its new steady-state. Also, the hope for 
subsequently increasing concentrations to support continuation of an unsuccessful 
antimicrobial therapy beyond a few days of treatment seems not justified for the 500 mg 
dose. In contrast, it may take several days until steady state is reached with the 1000 mg 
b.i.d dose, thus changes in the extent of inhibition and in the bacterial susceptibility e.g. due 
to emergence of resistance need to be taken into account during this period. The theoretical 
benefit of the high increase in plasma concentrations with increasing the dose to obtain 
better clinical outcomes remains to be assessed in clinical trials. Because it will take some 
time for the auto-inhibition of clearance to result in notably higher AUCs and the clinical 
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success probably depends on antimicrobial exposure during the first day(s) of therapy, the 
clinical benefit of the auto-inhibition might be less pronounced than predicted by the 
steady-state AUCs. For the same reasons, it might be reasonable considering a 
clarithromycin loading dose. 
Thus, the developed semi-mechanistic population PK model has the advantage of the ability 
to describe both the concentration-time course of clarithromycin concentrations and of the 
inhibitory action on CYP3A, and especially the change of its clearance over time. The model 
does not incorporate “all” underlying mechanisms, such as clarithromycin first pass 
metabolism and a separate time course for inhibition of intestinal and hepatic CYP3A 
enzymes. However, the model was still useful for the assessment of a possible dose 
adjustment, as well as for the purpose of further pharmacokinetic/pharmacodynamic 
considerations and model development activities.  
 
 
 
4.3 Dextromethorphan 
The main objective of this study was to quantify the metabolic activity of attributable to 
individual CYP2D6 alleles using dextromethorphan as a probe drug. 
Based on the final model estimates, the activity of the *1 allele is about two-fold higher than 
*2 allele. This result supports pervious in vitro results obtained for the substrate 
dextromethorphan where the same ratio was found (Bapiro et al. 2002). Furthermore, this 
study shows that the metabolic clearance of *41 allele is markedly less than that of the 
CYP2D6 *1 allele. While it is well-known that the activity for the *41 allele is lower than that 
for *1 and *2 alleles, this is the first quantitative estimate for the respective in vivo activity. 
The mean CYP2D6 mediated clearance CLCYP2D6 is about 15030 L/h in subjects who carry the 
CYP2D6 *1/*1x2 genotype, whereas it is about 170 L/h in subjects who carry two 
CYP2D6*41/*41 alleles, and obviously zero in the subpopulation carrying two dysfunctional 
alleles such as CYP2D6 *4/*4 genotype. This wide range of reflects the interindividual 
difference in the metabolic activity of CYP2D6 enzyme. 
The obtained results that *1 allele is related to an about 2-fold higher activity than the *2 
alleles is in contradiction to the assumption of equal activity as was made for the activity 
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score (Gaedigk et al. 2008) and semi-quantitative scoring (Steimer et al. 2004) systems. 
Similarly, in the previous systems (Steimer et al. 2004; Gaedigk et al. 2008) the presumed 
value for *41 allele was about half of the wild-type *1 allele, which is in contrast with the 
estimated difference in this study (~ 60 fold). Dextromethorphan pharmacokinetics for these 
different scenarios were simulated based on final parameter estimates (see 
dextromethorphan results Figure 31). The new results warrant further evaluation for other 
CYP2D6 substrates since previous studies suggested that the allelic activity of CYP2D6 
issubstrate dependent (Kirchheiner et al. 2004b; Shen et al. 2007; Kusama et al. 2009).   
 
The final model is able to describe the pharmacokinetic profiles of dextromethorphan and its 
major metabolite adequately. In this model, inclusion of the hypothetical metabolism 
compartment was able to explain the appearance of dextrorphan in plasma before 
dextromethorphan. The presented model shares some features with previously reported 
models that have been successfully applied to describe first-pass metabolism (Moghadamnia 
et al. 2003; Levi et al. 2007). The specific features in the presented model for 
dextromethorphan are that, (i) activity of active alleles of CYP2D6 were estimated 
separately, (ii) urinary data of both parent and metabolite were included in the model and 
simultaneously evaluated with plasma data; (iii) it can be extended to estimate the activity 
of other additional alleles such as *9, *10, and *17 alleles. These features increase 
applicability of the model. Clinical implications of these features remain to be ascertained. 
The presented results are in line with published data assuming a two-compartment model 
for dextromethorphan (Moghadamnia et al. 2003; Duedahl et al. 2005) and one-
compartment models for dextrorphan (Moghadamnia et al. 2003). The absorption rate 
constant estimate is about 0.25 h-1, which is in the range of previously reported values of 2.6 
h-1 (Moghadamnia et al. 2003) and 0.1 h-1 (Silvasti et al. 1987). The lag time was estimated to 
be 0.31 h, which is also within the range of previous studies with 0.8 h (Moghadamnia et al. 
2003) and 0.087 h (Duedahl et al. 2005). The model estimates for the apparent central and 
peripheral volumes of distribution of dextromethorphan in this study are smaller 648 L and 
1560 L compared with the previous ones 961 L and 1951 L (Moghadamnia et al. 2003). The 
volume of distribution of dextrorphan with 419 L is smaller than the previously reported 
value 650 L (Albers et al. 1995) and 3776 L (Moghadamnia et al. 2003), but higher than other 
reported value 109 L (Demirbas et al. 1998). The significant role of urine pH as a covariate to 
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explaining the variability of dextromethorphan between individuals is in agreement with a 
previous study, where urinary pH led to about 20-fold variation in the urinary metabolic ratio 
(Labbe et al. 2000). Taken together, these comparisons suggest that the developed model is 
valid.  
The goodness-of-fit plots (see dextromethorphan results Figure 27) show a possible 
overestimation of some dextromethorphan and dextrorphan concentrations due to model 
misspecification which is a semimechanistic rather than a fully mechanistic model. This may 
be explained by the existence of other sources of variability that could not be taken in to 
account in the final model. Possible sources could be the interindividual variability in 
CYP3A4/5, incomplete description of the first pass metabolism like the formation of 
methoxymorphinan from dextromethorphan, the lack of modeling the metabolic fate of 
dextrorphan, the possible contribution of glucuronidation, and inter-study variability. The 
interaction between the final model and the study design can be seen from the simulated 
predictive check plots (see dextromethorphan results Figure 29). The noticed overestimation 
may be also explained in part by the fact that many samples as in the terminal phase of 
plasma dextrorphan profiles had concentrations below the lower limit of quantification. 
However, generally these inadequately fitted concentrations form only a negligible fraction 
of the whole data set.  
 
4.4 Phenprocoumon 
In the present study, phenprocoumon PK and PD parameters were estimated by a semi-
mechanistic model in patient population and found that exposure depends on the metabolic 
activity of CYP2C9 variants, individuals´ age, and weight, while the response depends on 
VKORCI variants. The parameter estimates which were obtained also taking metabolite 
concentrations into account enable a genotype-based dose adjustment. 
 
The mean apparent total clearance of phenprocoumon in this population was 0.037 L/h and 
ranged from 0.012 to 0.077 L/h depending on the CYP2C9 polymorphisms, age, and weight. 
Previous studies showed an apparent clearance of 0.04-0.06 L/h (Kitteringham et al. 1984; 
Russmann et al. 2001; Kirchheiner et al. 2004c), which is in agreement with this evaluation. 
The estimated fraction of CYP2C9-mediated clearances leading to 7-OH-PPC formation (49%) 
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was more than 3-fold compared with that resulting in 4´-OH-PPC formation (14%). This is in 
agreement with previous findings that demonstrated the higher affinity of CYP2C9 to form 
the 7-hydroxy metabolite (Ufer et al. 2004c). The model underestimates the higher 
concentrations of metabolites (see phenprocoumon results Figure 35). This is most probably 
caused by model mis-specifications since the formation of these metabolites, mainly the 4´-
OH metabolite, is also mediated by other CYP enzymes (Ufer et al. 2004b; Ufer et al. 2004c; 
Kammerer et al. 2005). However, based on the available data, modelling such additional 
pathway was unsuccessful. 
 
The proposed linear PD model is quite simple and approximates the biological process of 
increasing INR values after phenprocoumon treatment. Its performance at the observed 
concentrations in this study is reasonably well. The limited INR range did not enable to use a 
more complex model, which therefore cannot be extrapolated to higher concentrations. This 
type of pharmacodynamic models has also been applied to describe warfarin concentration-
effect relationship (Sheiner 1969; Holford 1986). In the absence of drug, the model mimics 
normal INR value through the assumed basic value of unity (Harrington et al. 2008).  
 
In previous clinical pharmacokinetic studies on phenprocoumon, a higher metabolic capacity 
for the CYP2C9*1 allele compared with the *3 allele after single doses in healthy population 
was reported (Kirchheiner et al. 2004c). In the present study, the activity of *2 and *3 
variants of CYP2C9 was found to be 47% and 77% lower than that of *1 allele (see 
phenprocoumon results Table 13). The apparent total clearance in carriers of CYP2C9*1/*1 
genotypes was clearly higher than that in CYP2C9*3 homozygous individuals (0.042 L/h vs. 
0.022 L/h). In general, these results are in concordance with previous phenprocoumon 
studies that have reported the important role of CYP2C9 genotypes (Hummers-Pradier et al. 
2003; Schalekamp et al. 2004; Qazim et al. 2008; Stehle et al. 2008; Werner et al. 2009). The 
slightly more pronounced differences in clearance estimates (2-fold) compared to reported 
differences in empirical doses (1.5-fold) suggests that doctors are reluctant to prescribe 
required doses at the extremes of the dose range. A simulation of the impact of different 
CYP2C9 genotypes on steady state phenprocoumon concentrations is shown in Figure 40 
(see phenprocoumon results). This figure also shows the longer time elapsed until 
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phenprocoumon reaches its steady state in *3/*3 carriers compared with wild type *1/*1 
genotype carriers. 
 
Among tested covariates, VKORC1 polymorphisms variation was the only covariate that 
showed an impact on the pharmacodynamic model by modifying the sensitivity to 
phenprocoumon concentration reflecting different level of INR (see phenprocoumon results 
Table 14). These scenarios can be clearly observed in Figure 41 (see phenprocoumon 
results). The estimated difference in the INR for VKORC1 polymorphism suggests a significant 
increase in the anticoagulation sensitivity in VKORC1 TT carriers, indicated by notable higher 
estimates of the sensitivity factor compared with wild-type CC carriers (0.83 vs. 0.42). 
Correspondingly, the concentrations required to achieve an INR value of 2.5 for carriers of 
the VKORC1 TT variant was calculated to be 2-fold smaller compared with a homozygous 
VKORC1 CC carrier (1.82 vs. 3.57 µg/ml). The magnitude of these differences is very similar 
to empirical dose differences reported for patients under phenprocoumon therapy 
(Schalekamp et al. 2007; Stehle et al. 2008; Werner et al. 2009).  
 
It has been demonstrated that carriers of a combination of a low activity CYP2C9 variant and 
a high sensitivity VKORC1 polymorphism need more accurate dose adjustment to avoid 
increased risk of severe over-anticoagulation (Ufer 2005b; Schalekamp et al. 2007; Stehle et 
al. 2008). While the present study was not aimed to study the risk of bleeding, the 
consistency of results across studies suggests that INR is an appropriate surrogate parameter 
also for the comparison between genotypes. The required daily dose needed to maintain an 
INR value of 2.5 at steady state for subjects with 2C9*1/*1 - VKORC1 CC genotypes was 
calculated to be approximately 2-fold higher than that required for 2C9*3/*3 - VKORC1 CC 
genotype carrier and 4-fold higher than that required for 2C9*3/*3 - VKORC1 TT carrier (see 
phenprocoumon results Table 14). The magnitude of differences supports that prospective 
dose adjustments based on both CYP2C9 and VKORC1 genotypes may be beneficial for 
patient under phenprocoumon therapy (Hummers-Pradier et al. 2003; Schalekamp et al. 
2004; Qazim et al. 2008; Stehle et al. 2008; Werner et al. 2009).  
 
The additional information such as the severity of the patient’s disease, liver and renal 
functions, CYP3A5 genotypes, CYP3A phenotypes, plasma concentration of further hydroxyl 
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metabolites, enantioselective concentrations of phenprocoumon and its metabolites were 
not available.  
The presented study has several limitations; the sampling was limited to a single observation 
per patient, data were obtained from a heterogeneous population and the small 
(therapeutic) range in observed INR values did not allow for assessment of a full PD model. 
The structure of the presented semi-mechanistic PK model is not only a way to evaluate the 
role of CYP polymorphisms but it makes use of all available information with the following 
additional features beyond mere estimation of PK parameters: (i) it provides a tool to 
evaluate the individual clearance attributable to each allele involved in the total metabolic 
clearance; (ii) it increases the model applicability to incorporate other metabolic pathways; 
(iii) it may be used to predict drug profiles of genotypes not observed in this population 
(such as CYP2C9 *3/*3); and (iv) it may provide a dosage scheme for transition from one 
drug to another (e.g. warfarin to phenprocoumon).  
Due to sampling limitation to one sample of parent drug and its metabolites as well as the 
residual error of INR per subject, it was not possible to estimate residual errors of these 
vectors. Fixing these error terms to values like assay limits or prior information gave a 
chance to assess the interindividual variability and influencing covariates on the PK and PD 
parameter estimates, however these estimates may be biased with respect to the point 
estimates. Changing the fixed values within a factor of ten up and down the limits of 
quantifications was associated with different point estimates of model parameters. Higher 
and lower residual error values led to significant deterioration in both accuracy and precision 
of the model, however varying the error around assay limitations resulted in greater 
precision of parameter estimates. The deterioration effect of very high residual error values 
has been observed in previous study on animals (Ette et al. 1995). The number of individuals 
under the study (278 patients) was large enough to ensure precise parameter estimates. 
Because metabolite data were evaluated simultaneously with parent concentration, bias in 
model estimates is expected to be reduced. Since the “true” parameter estimates are 
unknown, neither the precision of estimates nor the degree of bias relative to true values 
could be quantified. The PK model was more sensitive than the PD model to initial estimates 
as the former contains more parameters to be estimated compared with PD model, but data 
would allow a prospective dose adjustment for phenpprocoumon, with subsequent check of 
INR. 
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5.1 Fluorescein 
The fluorescein study demonstrated that the bioavailability of fluorescein is superior when 
given as lyophilisate in comparison to eye drops in the anterior eye segment. A less 
pronounced increase in systemic bioavailability was seen via the ocular route, which is 
probably the result of a lower early loss of fluorescein for ocular absorption from the 
lyophilisate formulation. Depending on the physicochemical properties of a drug, this may 
be essential for achieving effective drug concentrations in the eye for a sufficient period of 
time. These advantages of the lyophilisate formulation over conventional eye drops suggest 
that lyophilisate is the formulation of choice to fulfill such needs in ophthalmology. Studies 
with other drugs, including direct quantification of ocular and systemic concentrations, are 
needed to assess whether this is general property of ocular lyophilisate preparations. 
 
 
5.2 Clarithromycin 
The clarithromycin study identified and quantified a time-dependent decrease of 
clarithromycin clearance in a non-linear fashion, which was completed on the 2nd day of 
treatment for the 500 mg bid doses. Reaching steady state was predicted to take several 
days for a 1000 mg bid dose. A semi-mechanistic population pharmacokinetic model for 
clarithromycin and its 14-(R) hydroxy metabolite was developed, which provides an 
adequate description of the time course of clearance inhibition within the used regimen. The 
seemingly atypical absorption process could be the result of saturable / inhibited first pass 
metabolism and may contribute to the overall nonlinear profiles of clarithromycin. The 
presented model serves as a useful tool to predict clarithromycin plasma concentrations and 
provides a rationale to improve its safety with regard to drug-drug interactions and its 
efficacy based on PK/PD consideration. The applicability of the model in the presence of 
additional CYP3A ligands (inhibitors or substrates) and the potential clinical benefit of the 
pronounced increase in plasma concentrations with increasing the clarithromycin dose 
remain to be assessed in further clinical trials. 
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5.3 Dextromethorphan 
Dextromethorphan data evaluation ended up with a final population model that adequately 
described dextromethorphan and dextrorphan pharmacokinetics in healthy Caucasian men. 
The results confirmed that individual CYP2D6 genotype and to a lesser degree urine pH 
contribute to the variability in pharmacokinetic profiles of dextromethorphan. The estimated 
quantitative differences in the metabolic capacity of individual CYP2D6 alleles, including *1, 
*2 and *41, suggest that existing scoring systems to predict CYP2D6 activity from CYP2D6 
genotype need to be refined. Whether the observed activity differences between functional 
alleles for dextromethorphan as a substrate are the same for other substrates remains to be 
assessed (Fuhr 2009). 
 
 
5.4 Phenprocoumon 
The phenprocoumon study presented a semi-mechanistic model that provided quantitative 
estimates for the impact of subject genotype, i.e. CYP2C9 and VKORC1 polymorphisms and 
of other covariates of phenprocoumon PK/PD profiles. An algorithm was derived from the 
results in order to predict individual weekly doses required to achieve a given INR. While this 
procedure makes use of existing knowledge, it would be desirable to study its clinical utility 
in prospective clinical trials.  
 
 
 
SUMMARY 
 
118 
 
6 SUMMARY 
 
The major message from these analyses is that modelling pharmacokinetics and 
pharmacodynamics, based on previous knowledge and by utilizing the benefits of readily 
available techniques, are best interpreted in term of how much they change our view 
regarding these complex processes rather than expecting them to tell us what we should 
end up believing. 
 
The ophthalmic lyophilisate formulation has been known for its safety, tolerability, and 
ability to achieve higher concentrations of a drug in the internal tissue of the eye compared 
with the conventional eye drop. Based on this prior information, population 
pharmacokinetic modelling was executed and quantified an improvement in the absorption 
phase. These outcomes will generate novel concept to improve ocular drug delivery 
straightforward with patient care improvement. 
 
Modelling clarithromycin auto-inhibition started from the previous knowledge that 
clarithromycin decreases its own clearance with repeated dosing. A significant quantitative 
description of the size of inhibition boosts the faith in it to something approaching clinical 
impacts in efficacy of the administered doses, drug interaction and/or dose adjustment.  
The final model provides parameters for dose adjustment depending on patient body weight 
and MICs required for susceptible pathogen eradication. Combining available information 
about the MIC of a pathogen with the model parameter estimates provided a useful means 
to develop ideas toward optimization of therapy.  
 
The dextromethorphan study aimed to provide a clear picture of the metabolic activity of 
individual CYP2D6 alleles frequently observed in a healthy Caucasian population. Evaluations 
were based on prior knowledge of highly variable metabolism of CYP2D6 substrates, that is 
heavily dependent on CYP2D6 genotype, and the problem that phenotypic prediction is still 
pawned by the variability of metabolic activity of different alleles. Once the impact of 
individual alleles is quantitatively and significantly estimated, confidence in this approach is 
improved. These observations call for further evaluation of ethnic, substrate and disease 
impact, but for now it can be stated that these information are “highly” clinical relevant and 
significant towards therapeutic optimization. 
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The phenprocoumon study aimed to identify genetic and demographic covariates for dose-
exposure response in a Caucasian population. Applications of previous knowledge of the role 
of evaluated covariates, led to confidence in the differential impact of both CYP2C9 
polymorphisms on the exposure profiles and the contribution of VKORC1 polymorphisms to 
the overall phenprocoumon response. In addition to these findings, the differential activity 
of CYP2C9 alleles provided understanding of the importance of individualised drug dosing 
(based on genetic and demographic information) to phenprocoumon PK-PD profiles. This is 
not only of clinical importance in order to avoid overanticoagulation or therapy failure, but it 
will also decrease therapy expenses. 
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